

SARS-CoV-2 Reverse Genetics Reveals a Variable Infect

Cell

182, 429-446.e14

DOI: [10.1016/j.cell.2020.05.042](https://doi.org/10.1016/j.cell.2020.05.042)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Seroprevalence of SARS-CoV-2 antibodies in people with an acute loss in their sense of smell and/or taste in a community-based population in London, UK: An observational cohort study. PLoS Medicine, 2020, 17, e1003358.	3.9	56
2	Experimental and in silico evidence suggests vaccines are unlikely to be affected by D614G mutation in SARS-CoV-2 spike protein. Npj Vaccines, 2020, 5, 96.	2.9	56
3	A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures. Nature, 2020, 586, 560-566.	13.7	527
4	Reducing transmission of SARS-CoV-2 in ophthalmology with nasal and oral decontamination. Therapeutic Advances in Ophthalmology, 2020, 12, 251584142095139.	0.8	1
5	Syncytia formation by SARS-CoV-2-infected cells. EMBO Journal, 2020, 39, e106267.	3.5	361
6	High Potency of a Bivalent Human VH Domain in SARS-CoV-2 Animal Models. Cell, 2020, 183, 429-441.e16.	13.5	100
7	A Mouse-Adapted SARS-CoV-2 Induces Acute Lung Injury and Mortality in Standard Laboratory Mice. Cell, 2020, 183, 1070-1085.e12.	13.5	472
8	Thermodynamic equilibrium dose-response models for MERS-CoV infection reveal a potential protective role of human lung mucus but not for SARS-CoV-2. Microbial Risk Analysis, 2020, 16, 100140.	1.3	27
9	Toward Understanding Molecular Bases for Biological Diversification of Human Coronaviruses: Present Status and Future Perspectives. Frontiers in Microbiology, 2020, 11, 2016.	1.5	11
10	Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults. New England Journal of Medicine, 2020, 383, 2427-2438.	13.9	1,242
11	Human Lung Stem Cell-Based Alveolospheres Provide Insights into SARS-CoV-2-Mediated Interferon Responses and Pneumocyte Dysfunction. Cell Stem Cell, 2020, 27, 890-904.e8.	5.2	275
12	A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19. Nature Communications, 2020, 11, 5214.	5.8	179
13	As Plain as the Nose on Your Face: The Case for A Nasal (Mucosal) Route of Vaccine Administration for Covid-19 Disease Prevention. Frontiers in Immunology, 2020, 11, 591897.	2.2	14
14	Strategies and Advances in Combating COVID-19 in China. Engineering, 2020, 6, 1076-1084.	3.2	16
15	SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature, 2020, 586, 567-571.	13.7	1,153
16	Expression of SARS-CoV-2 entry factors in lung epithelial stem cells and its potential implications for COVID-19. Scientific Reports, 2020, 10, 17772.	1.6	37
17	Airborne Particulate Matter and SARS-CoV-2 Partnership: Virus Hitchhiking, Stabilization and Immune Cell Targeting – A Hypothesis. Frontiers in Immunology, 2020, 11, 579352.	2.2	16
18	Swine acute diarrhea syndrome coronavirus replication in primary human cells reveals potential susceptibility to infection. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 26915-26925.	3.3	104

#	ARTICLE	IF	CITATIONS
19	Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity. <i>Cell</i> , 2020, 183, 996-1012.e19.	13.5	1,494
20	Pulmonary immune responses against SARS-CoV-2 infection: harmful or not?. <i>Intensive Care Medicine</i> , 2020, 46, 1897-1900.	3.9	20
21	Gene expression and <i>in situ</i> protein profiling of candidate SARS-CoV-2 receptors in human airway epithelial cells and lung tissue. <i>European Respiratory Journal</i> , 2020, 56, 2001123.	3.1	138
22	Direct Exposure to SARS-CoV-2 and Cigarette Smoke Increases Infection Severity and Alters the Stem Cell-Derived Airway Repair Response. <i>Cell Stem Cell</i> , 2020, 27, 869-875.e4.	5.2	74
23	Aerosol Transmission of SARS-CoV-2: Physical Principles and Implications. <i>Frontiers in Public Health</i> , 2020, 8, 590041.	1.3	111
24	Risk for COVID-19 infection in patients with tobacco smoke-associated cancers of the upper and lower airway. <i>European Archives of Oto-Rhino-Laryngology</i> , 2020, 278, 2695-2702.	0.8	7
25	Modeling Multi-organ Infection by SARS-CoV-2 Using Stem Cell Technology. <i>Cell Stem Cell</i> , 2020, 27, 859-868.	5.2	27
26	Airborne Transmission of COVID-19: Aerosol Dispersion, Lung Deposition, and Virus-Receptor Interactions. <i>ACS Nano</i> , 2020, 14, 16502-16524.	7.3	109
27	Actionable Cytopathogenic Host Responses of Human Alveolar Type 2 Cells to SARS-CoV-2. <i>Molecular Cell</i> , 2020, 80, 1104-1122.e9.	4.5	94
28	Covid-19-Associated Pulmonary Aspergillosis: The Other Side of the Coin. <i>Vaccines</i> , 2020, 8, 713.	2.1	23
29	SARS-CoV-2 Receptor Angiotensin I-Converting Enzyme Type 2 (ACE2) Is Expressed in Human Pancreatic Î2-Cells and in the Human Pancreas Microvasculature. <i>Frontiers in Endocrinology</i> , 2020, 11, 596898.	1.5	144
30	SARS-CoV-2 D614G variant exhibits efficient replication <i>ex vivo</i> and transmission <i>in vivo</i> . <i>Science</i> , 2020, 370, 1464-1468.	6.0	808
31	Long-Term Modeling of SARS-CoV-2 Infection of <i>In Vitro</i> Cultured Polarized Human Airway Epithelium. <i>MBio</i> , 2020, 11, .	1.8	80
32	Are patients with chronic rhinosinusitis with nasal polyps at a decreased risk of COVID-19 infection?. <i>International Forum of Allergy and Rhinology</i> , 2020, 10, 1182-1185.	1.5	18
33	A Look Behind the Scenes at COVID-19: National Strategies of Infection Control and Their Impact on Mortality. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 5616.	1.2	22
34	A New Natural Defense Against Airborne Pathogens. <i>QRB Discovery</i> , 2020, 1, e5.	0.6	10
35	Non-neuronal expression of SARS-CoV-2 entry genes in the olfactory system suggests mechanisms underlying COVID-19-associated anosmia. <i>Science Advances</i> , 2020, 6, .	4.7	865
36	Type I and Type III Interferons Restrict SARS-CoV-2 Infection of Human Airway Epithelial Cultures. <i>Journal of Virology</i> , 2020, 94, .	1.5	250

#	ARTICLE	IF	CITATIONS
37	Acute onset olfactory/taste disorders are associated with a high viral burden in mild or asymptomatic SARS-CoV-2 infections. <i>International Journal of Infectious Diseases</i> , 2020, 99, 19-22.	1.5	23
38	Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. <i>New England Journal of Medicine</i> , 2020, 383, 1544-1555.	13.9	936
39	How does SARS-CoV-2 cause COVID-19?. <i>Science</i> , 2020, 369, 510-511.	6.0	159
40	A Rosetta Stone for Understanding Infectious Drops and Aerosols. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2020, 9, 413-415.	0.6	96
41	First contact: the role of respiratory cilia in host-pathogen interactions in the airways. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2020, 319, L603-L619.	1.3	103
42	Impact of climate and ambient air pollution on the epidemic growth during COVID-19 outbreak in Japan. <i>Environmental Research</i> , 2020, 190, 110042.	3.7	97
43	Significant Unresolved Questions and Opportunities for Bioengineering in Understanding and Treating COVID-19 Disease Progression. <i>Cellular and Molecular Bioengineering</i> , 2020, 13, 259-284.	1.0	5
44	SARS-CoV-2 and Health Care Worker Protection in Low-Risk Settings: a Review of Modes of Transmission and a Novel Airborne Model Involving Inhalable Particles. <i>Clinical Microbiology Reviews</i> , 2020, 34, .	5.7	45
45	Coronavirus Disease-19 and Otolaryngology/Neurotology. <i>Otolaryngologic Clinics of North America</i> , 2020, 53, 1153-1157.	0.5	2
46	Understanding the complexities of SARS-CoV2 infection and its immunology: A road to immune-based therapeutics. <i>International Immunopharmacology</i> , 2020, 88, 106980.	1.7	31
47	High affinity binding of SARS-CoV-2 spike protein enhances ACE2 carboxypeptidase activity. <i>Journal of Biological Chemistry</i> , 2020, 295, 18579-18588.	1.6	82
48	Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2. <i>Cell</i> , 2020, 183, 1367-1382.e17.	13.5	420
49	Neurological injuries in COVID-19 patients: direct viral invasion or a bystander injury after infection of epithelial/endothelial cells. <i>Journal of NeuroVirology</i> , 2020, 26, 631-641.	1.0	38
50	Severe Acute Respiratory Syndrome Coronavirus 2 Impact on the Central Nervous System: Are Astrocytes and Microglia Main Players or Merely Bystanders?. <i>ASN Neuro</i> , 2020, 12, 175909142095496.	1.5	71
51	Prevalence of Chemosensory Dysfunction in COVID-19 Patients: A Systematic Review and Meta-analysis Reveals Significant Ethnic Differences. <i>ACS Chemical Neuroscience</i> , 2020, 11, 2944-2961.	1.7	189
52	A molecular trap against COVID-19. <i>Science</i> , 2020, 369, 1167-1168.	6.0	7
53	Elevated FiO ₂ increases SARS-CoV-2 co-receptor expression in respiratory tract epithelium. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2020, 319, L670-L674.	1.3	11
54	Cell and animal models of SARS-CoV-2 pathogenesis and immunity. <i>DMM Disease Models and Mechanisms</i> , 2020, 13, .	1.2	46

#	ARTICLE	IF	CITATIONS
55	SARS-CoV-2 Infection of Pluripotent Stem Cell-Derived Human Lung Alveolar Type 2 Cells Elicits a Rapid Epithelial-Intrinsic Inflammatory Response. <i>Cell Stem Cell</i> , 2020, 27, 962-973.e7.	5.2	266
56	Of Mice and Men: The Coronavirus MHV and Mouse Models as a Translational Approach to Understand SARS-CoV-2. <i>Viruses</i> , 2020, 12, 880.	1.5	116
57	Central Nervous System Targets and Routes for SARS-CoV-2: Current Views and New Hypotheses. <i>ACS Chemical Neuroscience</i> , 2020, 11, 2793-2803.	1.7	46
58	ACE2 Protein Landscape in the Head and Neck Region: The Conundrum of SARS-CoV-2 Infection. <i>Biology</i> , 2020, 9, 235.	1.3	40
59	The importance of vitamin d metabolism as a potential prophylactic, immunoregulatory and neuroprotective treatment for COVID-19. <i>Journal of Translational Medicine</i> , 2020, 18, 322.	1.8	118
60	Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2. <i>MBio</i> , 2020, 11, .	1.8	139
61	Anosmia in COVID-19: Underlying Mechanisms and Assessment of an Olfactory Route to Brain Infection. <i>Neuroscientist</i> , 2021, 27, 582-603.	2.6	238
62	<scp>SARSâ€CoV</scp>â€™ multifaceted interaction with the human host. Part <scp>II</scp>: Innate immunity response, immunopathology, and epigenetics. <i>IUBMB Life</i> , 2020, 72, 2331-2354.	1.5	29
63	In Vitro Efficacy of a Povidone-Iodine Nasal Antiseptic for Rapid Inactivation of SARS-CoV-2. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2020, 146, 1054.	1.2	57
64	Reply. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 1214-1215.	1.5	0
65	In vivo antiviral host transcriptional response to SARS-CoV-2 by viral load, sex, and age. <i>PLoS Biology</i> , 2020, 18, e3000849.	2.6	225
66	De novo design of picomolar SARS-CoV-2 miniprotein inhibitors. <i>Science</i> , 2020, 370, 426-431.	6.0	464
67	Heterogeneous groups of alveolar type II cells in lung homeostasis and repair. <i>American Journal of Physiology - Cell Physiology</i> , 2020, 319, C991-C996.	2.1	27
68	No small matter: a perspective on nanotechnology-enabled solutions to fight COVID-19. <i>Nanomedicine</i> , 2020, 15, 2411-2427.	1.7	19
69	COVID-19: Start with the nose. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 1214.	1.5	9
70	Viral Pandemics of the Last Four Decades: Pathophysiology, Health Impacts and Perspectives. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 9411.	1.2	85
71	The Microbiota/Host Immune System Interaction in the Nose to Protect from COVID-19. <i>Life</i> , 2020, 10, 345.	1.1	27
72	Recombinant ACE2 Expression Is Required for SARS-CoV-2 To Infect Primary Human Endothelial Cells and Induce Inflammatory and Procoagulative Responses. <i>MBio</i> , 2020, 11, .	1.8	92

#	ARTICLE	IF	CITATIONS
73	COVID-19 Pandemic Management Strategies and Outcomes in East Asia and the Western World: The Scientific State, Democratic Ideology, and Social Behavior. <i>Frontiers in Sociology</i> , 2020, 5, 575588.	1.0	5
75	Progenitor identification and SARS-CoV-2 infection in human distal lung organoids. <i>Nature</i> , 2020, 588, 670-675.	13.7	273
76	Temporal and spatial heterogeneity of host response to SARS-CoV-2 pulmonary infection. <i>Nature Communications</i> , 2020, 11, 6319.	5.8	203
77	Host metabolism dysregulation and cell tropism identification in human airway and alveolar organoids upon SARS-CoV-2 infection. <i>Protein and Cell</i> , 2021, 12, 717-733.	4.8	75
84	Oxygen Sensing and Viral Replication: Implications for Tropism and Pathogenesis. <i>Viruses</i> , 2020, 12, 1213.	1.5	18
85	Surgery during the COVID-19 pandemic. <i>Lancet, The</i> , 2020, 396, e74.	6.3	12
86	Integrate structural analysis, isoform diversity, and interferon-inductive propensity of ACE2 to predict SARS-CoV2 susceptibility in vertebrates. <i>Heliyon</i> , 2020, 6, e04818.	1.4	13
87	ACE2: The Only Thing That Matters?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, 161-163.	2.5	4
88	Cytokine Storm in COVID19: A Neural Hypothesis. <i>ACS Chemical Neuroscience</i> , 2020, 11, 1868-1870.	1.7	29
89	The Laboratory Diagnosis of Coronavirus Disease 2019” Frequently Asked Questions. <i>Clinical Infectious Diseases</i> , 2020, 71, 2996-3001.	2.9	52
90	Mechanisms and evidence of vertical transmission of infections in pregnancy including <sc>SARS-CoV</sc>s. <i>Prenatal Diagnosis</i> , 2020, 40, 1655-1670.	1.1	53
91	Nocturnal oxygen therapy as an option for early COVID-19. <i>International Journal of Infectious Diseases</i> , 2020, 98, 176-179.	1.5	9
92	Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus. <i>Cell</i> , 2020, 182, 812-827.e19.	13.5	3,551
93	COVID-19 and the Chemical Senses: Supporting Players Take Center Stage. <i>Neuron</i> , 2020, 107, 219-233.	3.8	256
94	Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice. <i>Cell Reports</i> , 2020, 32, 107940.	2.9	412
95	Review of indoor aerosol generation, transport, and control in the context of COVID-19. <i>International Forum of Allergy and Rhinology</i> , 2020, 10, 1173-1179.	1.5	126
96	Emerging Human Coronavirus Infections (SARS, MERS, and COVID-19): Where They Are Leading Us. <i>International Reviews of Immunology</i> , 2021, 40, 5-53.	1.5	20
97	COVID-19 Pulmonary and Olfactory Dysfunctions: Is the Chemokine CXCL10 the Common Denominator?. <i>Neuroscientist</i> , 2021, 27, 214-221.	2.6	49

#	ARTICLE	IF	CITATIONS
98	DockCoV2: a drug database against SARS-CoV-2. <i>Nucleic Acids Research</i> , 2021, 49, D1152-D1159.	6.5	42
99	Do saline water gargling and nasal irrigation confer protection against COVID-19?. <i>Explore: the Journal of Science and Healing</i> , 2021, 17, 127-129.	0.4	16
100	Hunting coronavirus by transmission electron microscopy—A guide to SARS-CoV-2-associated ultrastructural pathology in COVID-19 tissues. <i>Histopathology</i> , 2021, 78, 358-370.	1.6	90
101	SARS-CoV-2 infection, COVID-19 pathogenesis, and exposure to air pollution: What is the connection?. <i>Annals of the New York Academy of Sciences</i> , 2021, 1486, 15-38.	1.8	100
102	Immunity, endothelial injury and complement-induced coagulopathy in COVID-19. <i>Nature Reviews Nephrology</i> , 2021, 17, 46-64.	4.1	444
103	Causal impact of masks, policies, behavior on early covid-19 pandemic in the U.S.. <i>Journal of Econometrics</i> , 2021, 220, 23-62.	3.5	273
104	Snoring and obstructive sleep apnoea as risk factors in SARS-Cov-2: can nasal CPAP during sleep reduce pneumonia risk?. <i>Sleep and Biological Rhythms</i> , 2021, 19, 109-110.	0.5	4
105	A Shift Towards an Immature Myeloid Profile in Peripheral Blood of Critically Ill COVID-19 Patients. <i>Archives of Medical Research</i> , 2021, 52, 311-323.	1.5	13
106	Spike mutation D614G alters SARS-CoV-2 fitness. <i>Nature</i> , 2021, 592, 116-121.	13.7	1,380
107	A Versatile Reporter System To Monitor Virus-Infected Cells and Its Application to Dengue Virus and SARS-CoV-2. <i>Journal of Virology</i> , 2021, 95, .	1.5	21
108	Evaluation of Cloth Masks and Modified Procedure Masks as Personal Protective Equipment for the Public During the COVID-19 Pandemic. <i>JAMA Internal Medicine</i> , 2021, 181, 463.	2.6	118
109	Exploring the multifocal therapeutic approaches in COVID-19: A ray of hope. <i>International Immunopharmacology</i> , 2021, 90, 107156.	1.7	5
110	Tissue-Specific Immunopathology in Fatal COVID-19. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 192-201.	2.5	243
111	Molecular mechanism of inhibiting the SARS-CoV-2 cell entry facilitator TMPRSS2 with camostat and nafamostat. <i>Chemical Science</i> , 2021, 12, 983-992.	3.7	66
112	In well-differentiated primary human bronchial epithelial cells, TGF- β 1 and TGF- β 2 induce expression of furin. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2021, 320, L246-L253.	1.3	14
113	Targeting ACE2 for COVID-19 Therapy: Opportunities and Challenges. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2021, 64, 416-425.	1.4	68
114	Lung and Kidney ACE2 and TMPRSS2 in Renin-Angiotensin System Blocker-Treated Comorbid Diabetic Mice Mimicking Host Factors That Have Been Linked to Severe COVID-19. <i>Diabetes</i> , 2021, 70, 759-771.	0.3	18
115	Progress in Research on SARS-CoV-2 Infection Causing Neurological Diseases and Its Infection Mechanism. <i>Frontiers in Neurology</i> , 2020, 11, 592888.	1.1	8

#	ARTICLE	IF	CITATIONS
116	COVID-19: The Effect of Host Genetic Variations on Host-Virus Interactions. <i>Journal of Proteome Research</i> , 2021, 20, 139-153.	1.8	14
117	The central role of the nasal microenvironment in the transmission, modulation, and clinical progression of SARS-CoV-2 infection. <i>Mucosal Immunology</i> , 2021, 14, 305-316.	2.7	173
118	Hypertension delays viral clearance and exacerbates airway hyperinflammation in patients with COVID-19. <i>Nature Biotechnology</i> , 2021, 39, 705-716.	9.4	129
119	Impact of COVID-19 in solid organ transplant recipients. <i>American Journal of Transplantation</i> , 2021, 21, 925-937.	2.6	98
120	A mechanism-based pharmacokinetic model of remdesivir leveraging interspecies scaling to simulate COVID-19 treatment in humans. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021, 10, 89-99.	1.3	21
121	Interpretation of laboratory tests for prevention of the SARS-CoV-2 transmission. <i>Journal of Anesthesia</i> , 2021, 35, 374-377.	0.7	2
122	Integrating Proteomics for Facilitating Drug Identification and Repurposing During an Emerging Virus Pandemic. <i>ACS Infectious Diseases</i> , 2021, 7, 1303-1316.	1.8	1
123	Coronavirus biology and replication: implications for SARS-CoV-2. <i>Nature Reviews Microbiology</i> , 2021, 19, 155-170.	13.6	2,062
124	Multicenter Clinicopathologic Correlation of Kidney Biopsies Performed in COVID-19 Patients Presenting With Acute Kidney Injury or Proteinuria. <i>American Journal of Kidney Diseases</i> , 2021, 77, 82-93.e1.	2.1	138
125	Molecular diversity of coronavirus host cell entry receptors. <i>FEMS Microbiology Reviews</i> , 2021, 45, .	3.9	75
126	Nano-targeting lessons from the SARS-CoV-2. <i>Nano Today</i> , 2021, 36, 101012.	6.2	6
127	Naringenin is a powerful inhibitor of SARS-CoV-2 infection in vitro. <i>Pharmacological Research</i> , 2021, 163, 105255.	3.1	88
128	COVID-19: Topical agents and therapeutic prevention of nasal viral acquisition. <i>Dermatologic Therapy</i> , 2021, 34, e14454.	0.8	1
129	Low serum neutralizing anti-SARS-CoV-2 S antibody levels in mildly affected COVID-19 convalescent patients revealed by two different detection methods. <i>Cellular and Molecular Immunology</i> , 2021, 18, 936-944.	4.8	98
130	Beyond dexamethasone, emerging immunothrombotic therapies for COVID-19. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 845-857.	1.1	6
131	Viral infection and smell loss: The case of COVID-19. <i>Journal of Neurochemistry</i> , 2021, 157, 930-943.	2.1	43
132	Single-cell transcriptomic atlas of primate cardiopulmonary aging. <i>Cell Research</i> , 2021, 31, 415-432.	5.7	88
134	In vitro characterisation of SARS-CoV-2 and susceptibility of domestic ferrets (<i>Mustela putorius furo</i>). <i>Journal of Virology</i> , 2021, 95, e00111-21.	1.3	11

#	ARTICLE	IF	CITATIONS
135	COVID 19-Induced Smell and Taste Impairments: Putative Impact on Physiology. <i>Frontiers in Physiology</i> , 2020, 11, 625110.	1.3	42
137	Engineering SARS-CoV-2 using a reverse genetic system. <i>Nature Protocols</i> , 2021, 16, 1761-1784.	5.5	137
138	Prophylactic intranasal administration of a TLR2/6 agonist reduces upper respiratory tract viral shedding in a SARS-CoV-2 challenge ferret model. <i>EBioMedicine</i> , 2021, 63, 103153.	2.7	76
139	Single cell resolution of SARS-CoV-2 tropism, antiviral responses, and susceptibility to therapies in primary human airway epithelium. <i>PLoS Pathogens</i> , 2021, 17, e1009292.	2.1	76
140	A novel ACE2 isoform is expressed in human respiratory epithelia and is upregulated in response to interferons and RNA respiratory virus infection. <i>Nature Genetics</i> , 2021, 53, 205-214.	9.4	125
142	Neuroimaging a cytokine storm by transducing IL-1 \pm to hippocampal cornu ammonis: COVID-19 SARS-CoV-2. , 2021, , 107-117.		0
143	Increased focus on non-animal models for COVID-19 and non-COVID lung research. <i>European Respiratory Journal</i> , 2021, 57, 2004267.	3.1	2
144	Lipid nanoparticle formulation of niclosamide (nano NCM) effectively inhibits SARS-CoV-2 replication in vitro. <i>Precision Nanomedicine</i> , 2021, 4, 724-737.	0.4	11
145	A nano perspective behind the COVID-19 pandemic. <i>Nanoscale Horizons</i> , 2021, 6, 842-855.	4.1	1
146	Engineering a Reliable and Convenient SARS-CoV-2 Replicon System for Analysis of Viral RNA Synthesis and Screening of Antiviral Inhibitors. <i>MBio</i> , 2021, 12, .	1.8	22
147	RGD α -binding integrins and TGF β α 2 in SARS α CoV α 2 infections α novel targets to treat COVID α 19 patients?. <i>Clinical and Translational Immunology</i> , 2021, 10, e1240.	1.7	32
148	A scoping review of the pathophysiology of COVID-19. <i>International Journal of Immunopathology and Pharmacology</i> , 2021, 35, 205873842110480.	1.0	42
149	Vitamin A in resistance to and recovery from infection: relevance to SARS-CoV2. <i>British Journal of Nutrition</i> , 2021, 126, 1663-1672.	1.2	45
150	An overview of current COVID-19 vaccine platforms. <i>Computational and Structural Biotechnology Journal</i> , 2021, 19, 2508-2517.	1.9	99
151	Self-Organizing, Symmetry Breaking, Isogenic Human Lung Buds on Microchips Identify Alveolar Stem Cells as Novel Targets of SARS-CoV-2. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
152	COVID-19 in Brazil: spatial risk, social vulnerability, human development, clinical manifestations and predictors of mortality α a retrospective study with data from 59 695 individuals. <i>Epidemiology and Infection</i> , 2021, 149, e100.	1.0	15
153	Human induced pluripotent stem cells as a tool for disease modeling and drug screening for COVID-19. <i>Genetics and Molecular Biology</i> , 2021, 44, e20200198.	0.6	3
154	COVID-19 α The Potential Beneficial Therapeutic Effects α of Spironolactone during SARS-CoV-2 Infection. <i>Pharmaceuticals</i> , 2021, 14, 71.	1.7	33

#	ARTICLE	IF	CITATIONS
155	From impossible to possible: the lessons from the control of recent COVID-19 outbreaks in China. <i>International Journal of Biological Sciences</i> , 2021, 17, 1600-1612.	2.6	1
157	Similarities and Dissimilarities of COVID-19 and Other Coronavirus Diseases. <i>Annual Review of Microbiology</i> , 2021, 75, 19-47.	2.9	52
158	Influenza virus infection increases ACE2 expression and shedding in human small airway epithelial cells. <i>European Respiratory Journal</i> , 2021, 58, 2003988.	3.1	38
159	A PCR amplicon-based SARS-CoV-2 replicon for antiviral evaluation. <i>Scientific Reports</i> , 2021, 11, 2229.	1.6	27
160	COVID-19: Integrating the Complexity of Systemic and Pulmonary Immunopathology to Identify Biomarkers for Different Outcomes. <i>Frontiers in Immunology</i> , 2020, 11, 599736.	2.2	16
161	Rapid Development of SARS-CoV-2 Spike Protein Receptor-Binding Domain Self-Assembled Nanoparticle Vaccine Candidates. <i>ACS Nano</i> , 2021, 15, 2738-2752.	7.3	143
162	A SCID mouse-human lung xenograft model of SARS-CoV-2 infection. <i>Theranostics</i> , 2021, 11, 6607-6615.	4.6	8
164	A <i>Trans</i> -Complementation System for SARS-CoV-2. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
165	A Defense of the Classical Model of Transmission of Respiratory Pathogens. <i>Clinical Infectious Diseases</i> , 2021, 73, 1318.	2.9	4
166	Roles of Type I and III Interferons in COVID-19. <i>Yonsei Medical Journal</i> , 2021, 62, 381.	0.9	17
167	SARS-CoV-2 Entry Genes Expression in Relation with Interferon Response in Cystic Fibrosis Patients. <i>Microorganisms</i> , 2021, 9, 93.	1.6	4
169	Development and evaluation of inhalable composite niclosamide-lysozyme particles: A broad-spectrum, patient-adaptable treatment for coronavirus infections and sequalae. <i>PLoS ONE</i> , 2021, 16, e0246803.	1.1	43
171	Making sense of spike D614G in SARS-CoV-2 transmission. <i>Science China Life Sciences</i> , 2021, 64, 1062-1067.	2.3	8
172	Assessing the risk of COVID-19 from multiple pathways of exposure to SARS-CoV-2: Modeling in health-care settings and effectiveness of nonpharmaceutical interventions. <i>Environment International</i> , 2021, 147, 106338.	4.8	39
174	TOLERABILITY OF HALODINE ORAL AND NASAL ANTISEPTICS AS PART OF A SARS-COV-2 TRANSMISSION REDUCTION STRATEGY. , 2021, , 44-47.		0
175	Coinfection with influenza A virus enhances SARS-CoV-2 infectivity. <i>Cell Research</i> , 2021, 31, 395-403.	5.7	164
177	Clinical and whole genome characterization of SARS-CoV-2 in India. <i>PLoS ONE</i> , 2021, 16, e0246173.	1.1	12
179	A plasmid DNA-launched SARS-CoV-2 reverse genetics system and coronavirus toolkit for COVID-19 research. <i>PLoS Biology</i> , 2021, 19, e3001091.	2.6	163

#	ARTICLE	IF	CITATIONS
181	Comparative analysis of ACE2 protein expression in rodent, non-human primate, and human respiratory tract at baseline and after injury: A conundrum for COVID-19 pathogenesis. PLoS ONE, 2021, 16, e0247510.	1.1	18
182	SARS-CoV-2 Infection and Disease Modelling Using Stem Cell Technology and Organoids. International Journal of Molecular Sciences, 2021, 22, 2356.	1.8	13
183	Comparison of Antiviral Activity of Gemcitabine with 2-Fluoro-2-Deoxycytidine and Combination Therapy with Remdesivir against SARS-CoV-2. International Journal of Molecular Sciences, 2021, 22, 1581.	1.8	18
185	Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody. Science, 2021, 371, 823-829.	6.0	285
187	SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801. Nature, 2021, 591, 451-457.	13.7	320
188	In Vitro and In Vivo Models for Studying SARS-CoV-2, the Etiological Agent Responsible for COVID-19 Pandemic. Viruses, 2021, 13, 379.	1.5	53
189	COVID-19 Vaccines (Revisited) and Oral-Mucosal Vector System as a Potential Vaccine Platform. Vaccines, 2021, 9, 171.	2.1	43
190	Patterns of virus growth across the diversity of life. Integrative Biology (United Kingdom), 2021, 13, 44-59.	0.6	7
191	A Timely Call to Arms: COVID-19, the Circadian Clock, and Critical Care. Journal of Biological Rhythms, 2021, 36, 55-70.	1.4	22
193	Review of studies of severe acute respiratory syndrome related coronavirus-2 pathogenesis in human organoid models. Reviews in Medical Virology, 2021, 31, e2227.	3.9	10
194	A novel cell culture system modeling the SARS-CoV-2 life cycle. PLoS Pathogens, 2021, 17, e1009439.	2.1	102
195	The Good Treatment, the Bad Virus, and the Ugly Inflammation: Pathophysiology of Kidney Involvement During COVID-19. Frontiers in Physiology, 2021, 12, 613019.	1.3	12
196	Single-cell longitudinal analysis of SARS-CoV-2 infection in human airway epithelium identifies target cells, alterations in gene expression, and cell state changes. PLoS Biology, 2021, 19, e3001143.	2.6	180
197	Computational characterization of inhaled droplet transport to the nasopharynx. Scientific Reports, 2021, 11, 6652.	1.6	43
198	The Organoid Platform: Promises and Challenges as Tools in the Fight against COVID-19. Stem Cell Reports, 2021, 16, 412-418.	2.3	20
199	Whole genome analysis of more than 10 000 SARS-CoV-2 virus unveils global genetic diversity and target region of NSP6. Briefings in Bioinformatics, 2021, 22, 1106-1121.	3.2	13
200	Mechanistic Modeling of SARS-CoV-2 and Other Infectious Diseases and the Effects of Therapeutics. Clinical Pharmacology and Therapeutics, 2021, 109, 829-840.	2.3	70
201	Aptamer Blocking Strategy Inhibits SARS-CoV-2 Virus Infection. Angewandte Chemie - International Edition, 2021, 60, 10266-10272.	7.2	144

#	ARTICLE	IF	CITATIONS
202	SARS-CoV-2 cell tropism and multiorgan infection. <i>Cell Discovery</i> , 2021, 7, 17.	3.1	148
203	Should we discount the laboratory origin of COVID-19?. <i>Environmental Chemistry Letters</i> , 2021, 19, 2743-2757.	8.3	23
204	Animal Hosts and Experimental Models of SARS-CoV-2 Infection. <i>Chemotherapy</i> , 2021, 66, 1-9.	0.8	13
205	Generation and Characterization of Recombinant SARS-CoV-2 Expressing Reporter Genes. <i>Journal of Virology</i> , 2021, 95, .	1.5	37
206	Disruption of respiratory epithelial basement membrane in COVID-19 patients. <i>Molecular Biomedicine</i> , 2021, 2, 8.	1.7	4
207	Could targeting immunometabolism be a way to control the burden of COVID-19 infection?. <i>Microbes and Infection</i> , 2021, 23, 104780.	1.0	9
208	DNA methylation architecture of the ACE2 gene in nasal cells of children. <i>Scientific Reports</i> , 2021, 11, 7107.	1.6	21
209	Functional monocytic myeloid-derived suppressor cells increase in blood but not airways and predict COVID-19 severity. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	88
210	Review of the risk factors for SARS-CoV-2 transmission. <i>World Journal of Clinical Cases</i> , 2021, 9, 1499-1512.	0.3	4
211	Essentials in saline pharmacology for nasal or respiratory hygiene in times of COVID-19. <i>European Journal of Clinical Pharmacology</i> , 2021, 77, 1275-1293.	0.8	24
212	Aptamer Blocking Strategy Inhibits SARS-CoV-2 Virus Infection. <i>Angewandte Chemie</i> , 2021, 133, 10354-10360.	1.6	20
213	Profiling of the immune repertoire in COVID-19 patients with mild, severe, convalescent, or retesting-positive status. <i>Journal of Autoimmunity</i> , 2021, 118, 102596.	3.0	27
214	Updates on Anticoagulation and Laboratory Tools for Therapy Monitoring of Heparin, Vitamin K Antagonists and Direct Oral Anticoagulants. <i>Biomedicines</i> , 2021, 9, 264.	1.4	10
215	Mask-wearing and control of SARS-CoV-2 transmission in the USA: a cross-sectional study. <i>The Lancet Digital Health</i> , 2021, 3, e148-e157.	5.9	208
216	SARS-CoV-2 spike protein binding selectively accelerates substrate-specific catalytic activity of ACE2. <i>Journal of Biochemistry</i> , 2021, 170, 299-306.	0.9	13
218	Virus Eradication and Synthetic Biology: Changes with SARS-CoV-2?. <i>Viruses</i> , 2021, 13, 569.	1.5	3
219	Antiviral Activity of the Propylamylatin TM Formula against the Novel Coronavirus SARS-CoV-2 In Vitro Using Direct Injection and Gas Assays in Virus Suspensions. <i>Viruses</i> , 2021, 13, 415.	1.5	5
221	Amantadine Inhibits SARS-CoV-2 In Vitro. <i>Viruses</i> , 2021, 13, 539.	1.5	38

#	ARTICLE	IF	CITATIONS
222	Comparison of Subgenomic and Total RNA in SARS-CoV-2-Challenged Rhesus Macaques. <i>Journal of Virology</i> , 2021, 95, .	1.5	87
223	Consequences of coronavirus infections for primitive and mature hematopoietic cells: new insights and why it matters. <i>Current Opinion in Hematology</i> , 2021, 28, 231-242.	1.2	2
224	Wuhan to World: The COVID-19 Pandemic. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 596201.	1.8	115
226	Repurposing the Ebola and Marburg Virus Inhibitors Tilorone, Quinacrine, and Pyronaridine: <i>In Vitro</i> Activity against SARS-CoV-2 and Potential Mechanisms. <i>ACS Omega</i> , 2021, 6, 7454-7468.	1.6	56
227	SARS-CoV-2 infection of the oral cavity and saliva. <i>Nature Medicine</i> , 2021, 27, 892-903.	15.2	527
228	Transmissibility and transmission of respiratory viruses. <i>Nature Reviews Microbiology</i> , 2021, 19, 528-545.	13.6	446
231	The effect of coronaviruses on olfaction: systematic review. <i>Rhinology</i> , 2021, 59, 0-0.	0.7	10
233	Systems and Clinical Pharmacology of COVID-19 Therapeutic Candidates: A Clinical and Translational Medicine Perspective. <i>Journal of Pharmaceutical Sciences</i> , 2021, 110, 1002-1017.	1.6	14
234	Single-cell meta-analysis of SARS-CoV-2 entry genes across tissues and demographics. <i>Nature Medicine</i> , 2021, 27, 546-559.	15.2	261
235	Alpha-1 antitrypsin inhibits TMPRSS2 protease activity and SARS-CoV-2 infection. <i>Nature Communications</i> , 2021, 12, 1726.	5.8	86
236	SARS-CoV-2 may hijack GPCR signaling pathways to dysregulate lung ion and fluid transport. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2021, 320, L430-L435.	1.3	36
239	Generation of SARS-CoV-2 reporter replicon for high-throughput antiviral screening and testing. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	64
240	Mucosal immunity to severe acute respiratory syndrome coronavirus 2 infection. <i>Current Opinion in Infectious Diseases</i> , 2021, 34, 181-186.	1.3	34
241	The Combination of Bromelain and Acetylcysteine (BromAc) Synergistically Inactivates SARS-CoV-2. <i>Viruses</i> , 2021, 13, 425.	1.5	27
242	Disparate temperature-dependent virus-host dynamics for SARS-CoV-2 and SARS-CoV in the human respiratory epithelium. <i>PLoS Biology</i> , 2021, 19, e3001158.	2.6	79
244	Can Yogic Breathing Techniques Like Simha Kriya and Isha Kriya Regulate COVID-19-Related Stress?. <i>Frontiers in Psychology</i> , 2021, 12, 635816.	1.1	8
245	Stem cells of submucosal glands: their function as tissue stem cells and a reserve population for airway repair. , 2021, , 70-83.		0
247	Mechanisms of SARS-CoV-2-induced lung vascular disease: potential role of complement. <i>Pulmonary Circulation</i> , 2021, 11, 1-14.	0.8	34

#	ARTICLE	IF	CITATIONS
248	The SARS-CoV-2 and other human coronavirus spike proteins are fine-tuned towards temperature and proteases of the human airways. <i>PLoS Pathogens</i> , 2021, 17, e1009500.	2.1	91
249	COVID-19 and thrombosis: From bench to bedside. <i>Trends in Cardiovascular Medicine</i> , 2021, 31, 143-160.	2.3	152
250	Robust SARS-CoV-2 infection in nasal turbinates after treatment with systemic neutralizing antibodies. <i>Cell Host and Microbe</i> , 2021, 29, 551-563.e5.	5.1	87
251	Broad Severe Acute Respiratory Syndrome Coronavirus 2 Cell Tropism and Immunopathology in Lung Tissues From Fatal Coronavirus Disease 2019. <i>Journal of Infectious Diseases</i> , 2021, 223, 1842-1854.	1.9	33
252	Drug repurposing screens reveal cell-type-specific entry pathways and FDA-approved drugs active against SARS-Cov-2. <i>Cell Reports</i> , 2021, 35, 108959.	2.9	176
253	Organoid: a powerful tool to study lung regeneration and disease. <i>Cell Regeneration</i> , 2021, 10, 21.	1.1	25
255	Anti-cancer Therapy Leads to Increased Cardiovascular Susceptibility to COVID-19. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 634291.	1.1	6
256	The variant gambit: COVID-19's next move. <i>Cell Host and Microbe</i> , 2021, 29, 508-515.	5.1	305
257	Hypertension, a Moving Target in COVID-19. <i>Circulation Research</i> , 2021, 128, 1062-1079.	2.0	61
258	Critical ACE2 Determinants of SARS-CoV-2 and Group 2B Coronavirus Infection and Replication. <i>MBio</i> , 2021, 12, .	1.8	8
259	Fluticasone Propionate Suppresses Poly(I:C)-Induced ACE2 in Primary Human Nasal Epithelial Cells. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 655666.	1.8	11
261	COVID 19 HASTALARINDA TAT VE KOKU BOZUKLUKLARI. Sileyman Demirel Üniversitesi Tıp Fakültesi Dergisi, 0, , .	0.0	0
262	Multifunctional angiotensin converting enzyme 2, the SARS-CoV-2 entry receptor, and critical appraisal of its role in acute lung injury. <i>Biomedicine and Pharmacotherapy</i> , 2021, 136, 111193.	2.5	42
263	COVID-19 immune features revealed by a large-scale single-cell transcriptome atlas. <i>Cell</i> , 2021, 184, 1895-1913.e19.	13.5	512
265	Epigenetic regulation of ACE2, the receptor of the SARS-CoV-2 virus. <i>Genome</i> , 2021, 64, 386-399.	0.9	58
266	Discovery and functional interrogation of SARS-CoV-2 RNA-host protein interactions. <i>Cell</i> , 2021, 184, 2394-2411.e16.	13.5	141
267	Antiviral drug screen identifies DNA-damage response inhibitor as potent blocker of SARS-CoV-2 replication. <i>Cell Reports</i> , 2021, 35, 108940.	2.9	76
268	The pathogenic role of epithelial and endothelial cells in early-phase COVID-19 pneumonia: victims and partners in crime. <i>Modern Pathology</i> , 2021, 34, 1444-1455.	2.9	41

#	ARTICLE	IF	CITATIONS
270	Polymer-based nano-therapies to combat COVID-19 related respiratory injury: progress, prospects, and challenges. <i>Journal of Biomaterials Science, Polymer Edition</i> , 2021, 32, 1219-1249.	1.9	19
271	IL-6 modulation for COVID-19: the right patients at the right time?. , 2021, 9, e002285.		32
272	The olfactory nerve is not a likely route to brain infection in COVID-19: a critical review of data from humans and animal models. <i>Acta Neuropathologica</i> , 2021, 141, 809-822.	3.9	94
273	The first few days of a SARS-CoV-2 infection viewed at single-cell resolution. <i>PLoS Biology</i> , 2021, 19, e3001217.	2.6	2
274	Construction of Non-infectious SARS-CoV-2 Replicons and Their Application in Drug Evaluation. <i>Virologica Sinica</i> , 2021, 36, 890-900.	1.2	14
275	Sex Differences in the Induction of Angiotensin Converting Enzyme 2 (Ace-2) in Mouse Lungs after E-Cigarette Vapor Exposure and Its Relevance to Covid-19. <i>Journal of Investigative Medicine</i> , 2021, 69, 954-961.	0.7	14
278	A trans-complementation system for SARS-CoV-2 recapitulates authentic viral replication without virulence. <i>Cell</i> , 2021, 184, 2229-2238.e13.	13.5	51
280	Influenza virus and SARS-CoV-2: pathogenesis and host responses in the respiratory tract. <i>Nature Reviews Microbiology</i> , 2021, 19, 425-441.	13.6	202
281	SARS-CoV-2 induces double-stranded RNA-mediated innate immune responses in respiratory epithelial-derived cells and cardiomyocytes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	159
282	A Convenient and Biosafe Replicon with Accessory Genes of SARS-CoV-2 and Its Potential Application in Antiviral Drug Discovery. <i>Virologica Sinica</i> , 2021, 36, 913-923.	1.2	25
283	Human-Based Advanced in vitro Approaches to Investigate Lung Fibrosis and Pulmonary Effects of COVID-19. <i>Frontiers in Medicine</i> , 2021, 8, 644678.	1.2	31
284	SARS-CoV-2 RNA screening in routine pathology specimens. <i>Microbial Biotechnology</i> , 2021, 14, 1627-1641.	2.0	9
285	Perspective: the nose and the stomach play a critical role in the NZACE2-Pàari* (modified ACE2) drug treatment project of SARS-CoV-2 infection. <i>Expert Review of Clinical Immunology</i> , 2021, 17, 553-560.	1.3	10
286	Prevalent, protective, and convergent IgG recognition of SARS-CoV-2 non-RBD spike epitopes. <i>Science</i> , 2021, 372, 1108-1112.	6.0	210
287	5-hydroxycytidine Inhibits SARS-CoV-2 Through Lethal Mutagenesis But Is Also Mutagenic To Mammalian Cells. <i>Journal of Infectious Diseases</i> , 2021, 224, 415-419.	1.9	211
288	Characterization of an attenuated SARS-CoV-2 variant with a deletion at the S1/S2 junction of the spike protein. <i>Nature Communications</i> , 2021, 12, 2790.	5.8	26
289	Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses. <i>Nature</i> , 2021, 594, 553-559.	13.7	199
290	Pharmacological activation of STING blocks SARS-CoV-2 infection. <i>Science Immunology</i> , 2021, 6, .	5.6	123

#	ARTICLE	IF	CITATIONS
292	Research progress of traditional Chinese medicine against COVID-19. <i>Biomedicine and Pharmacotherapy</i> , 2021, 137, 111310.	2.5	57
294	Rapid endotheliitis and vascular damage characterize SARS-CoV-2 infection in a human lung-on-a-chip model. <i>EMBO Reports</i> , 2021, 22, e52744.	2.0	81
295	COVID-19-related anosmia is associated with viral persistence and inflammation in human olfactory epithelium and brain infection in hamsters. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	322
296	Relating Ventilatory Support and Drug Treatment Strategies to the Fundamental Pathophysiology in COVID-19 Illness. <i>European Medical Journal (Chelmsford, England)</i> , 0, , .	3.0	0
297	A randomized, double-blind, placebo-controlled phase 1 trial of inhaled and intranasal niclosamide: A broad spectrum antiviral candidate for treatment of COVID-19. <i>Lancet Regional Health - Europe</i> , The, 2021, 4, 100084.	3.0	45
298	Emerging role of air pollution and meteorological parameters in COVID-19. <i>Journal of Evidence-Based Medicine</i> , 2021, 14, 123-138.	0.7	12
299	Lower Gene Expression of Angiotensin Converting Enzyme 2 Receptor in Lung Tissues of Smokers With COVID-19 Pneumonia. <i>Biomolecules</i> , 2021, 11, 796.	1.8	2
300	Anti-SARS-CoV-2 IgY Isolated from Egg Yolks of Hens Immunized with Inactivated SARS-CoV-2 for Immunoprophylaxis of COVID-19. <i>Virologica Sinica</i> , 2021, 36, 1080-1082.	1.2	15
301	SARS-CoV-2 infection of primary human lung epithelium for COVID-19 modeling and drug discovery. <i>Cell Reports</i> , 2021, 35, 109055.	2.9	186
302	Persistent Nasal Inflammation 5 Months after Acute Anosmia in Patients with COVID-19. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 1319-1322.	2.5	10
303	Carrageenan-containing over-the-counter nasal and oral sprays inhibit SARS-CoV-2 infection of airway epithelial cultures. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2021, 320, L750-L756.	1.3	41
304	SARS-CoV-2 Induced Neurological Manifestations Entangles Cytokine Storm that Implicates for Therapeutic Strategies. <i>Current Medicinal Chemistry</i> , 2022, 29, 2051-2074.	1.2	5
307	Insights into SARS-CoV-2 Persistence and Its Relevance. <i>Viruses</i> , 2021, 13, 1025.	1.5	37
308	Possible effects of air temperature on COVID-19 disease severity and transmission rates. <i>Journal of Medical Virology</i> , 2021, 93, 5358-5366.	2.5	16
309	Human pluripotent stem cell-based organoids and cell platforms for modelling SARS-CoV-2 infection and drug discovery. <i>Stem Cell Research</i> , 2021, 53, 102207.	0.3	13
310	Nasopharyngeal Type-I Interferon for Immediately Available Prophylaxis Against Emerging Respiratory Viral Infections. <i>Frontiers in Immunology</i> , 2021, 12, 660298.	2.2	8
311	Platycodin D, a natural component of <i>Platycodon grandiflorum</i> , prevents both lysosome- and TMPRSS2-driven SARS-CoV-2 infection by hindering membrane fusion. <i>Experimental and Molecular Medicine</i> , 2021, 53, 956-972.	3.2	49
312	Pathophysiology of infection with SARS-CoV-2: What is known and what remains a mystery. <i>Respirology</i> , 2021, 26, 652-665.	1.3	44

#	ARTICLE	IF	CITATIONS
313	Asymptomatic and symptomatic SARS-CoV-2 infections elicit polyfunctional antibodies. <i>Cell Reports Medicine</i> , 2021, 2, 100275.	3.3	64
314	Clinical Efficacy of an Osmotic, Antiviral and Anti-Inflammatory Polymeric Nasal Film to Treat Covid-19 Early-Phase Respiratory Symptoms. <i>Open Access Journal of Clinical Trials</i> , 0, Volume 13, 11-20.	1.5	1
315	A Luciferase-EGFP Reporter System for the Evaluation of DNA Methylation in Mammalian Cells. <i>Molecular Biology</i> , 2021, 55, 742-751.	0.4	3
316	Direct derivation of human alveolospheres for SARS-CoV-2 infection modeling and drug screening. <i>Cell Reports</i> , 2021, 35, 109218.	2.9	38
318	Simple rapid in vitro screening method for SARS-CoV-2 anti-virals that identifies potential cytotoxicity-associated false positives. <i>Virology Journal</i> , 2021, 18, 123.	1.4	21
319	Breathing, speaking, coughing or sneezing: What drives transmission of SARS-CoV-2?. <i>Journal of Internal Medicine</i> , 2021, 290, 1010-1027.	2.7	97
320	Molecular PET/CT Profiling of ACE2 Expression In Vivo: Implications for Infection and Outcome from SARS-CoV-2. <i>Advanced Science</i> , 2021, 8, e2100965.	5.6	17
321	Prolonged SARS-CoV-2 cell culture replication in respiratory samples from patients with severe COVID-19. <i>Clinical Microbiology and Infection</i> , 2021, 27, 886-891.	2.8	51
322	Histopathological features in fatal COVID-19 acute respiratory distress syndrome. <i>Medicina Intensiva</i> , 2021, 45, 261-270.	0.4	17
324	Advancing lung organoids for COVID-19 research. <i>DMM Disease Models and Mechanisms</i> , 2021, 14, .	1.2	39
327	Anti-SARS-CoV-2 Vaccines and Monoclonal Antibodies Facing Viral Variants. <i>Viruses</i> , 2021, 13, 1171.	1.5	27
328	Viral Dynamics and Real-Time RT-PCR Ct Values Correlation with Disease Severity in COVID-19. <i>Diagnostics</i> , 2021, 11, 1091.	1.3	135
329	Estimating COVID-19 Infection and Severity Risks in Patients with Chronic Rhinosinusitis: A Korean Nationwide Cohort Study. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 2262-2271.e2.	2.0	27
331	Pathogenesis-based preexposure prophylaxis associated with a low risk of SARS-CoV-2 infection in healthcare workers at a designated COVID-19 hospital: a pilot study. <i>BMC Infectious Diseases</i> , 2021, 21, 536.	1.3	2
332	Do Changes in ACE-2 Expression Affect SARS-CoV-2 Virulence and Related Complications: A Closer Look into Membrane-Bound and Soluble Forms. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6703.	1.8	27
333	Defense of COVID-19 by Human Organoids. <i>Phenomics</i> , 2021, 1, 113-128.	0.9	8
334	A review of nasopharyngeal swab and saliva tests for SARS-CoV-2 infection: Disease timelines, relative sensitivities, and test optimization. <i>Journal of Surgical Oncology</i> , 2021, 124, 465-475.	0.8	14
335	Extracellular vesicles carry SARS-CoV-2 spike protein and serve as decoys for neutralizing antibodies. <i>Journal of Extracellular Vesicles</i> , 2021, 10, e12112.	5.5	44

#	ARTICLE	IF	CITATIONS
336	Nasal vaccination against SARS-CoV-2: Synergistic or alternative to intramuscular vaccines?. <i>International Journal of Pharmaceutics</i> , 2021, 603, 120686.	2.6	83
337	Laboratory Worker Self-Contamination with Noninfectious SARS-CoV-2 DNA Can Result in False-Positive Reverse Transcriptase PCR-Based Surveillance Testing. <i>Journal of Clinical Microbiology</i> , 2021, 59, e0072321.	1.8	8
340	The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity. <i>Lancet Respiratory Medicine</i> , 2021, 9, 622-642.	5.2	371
342	Studying SARS-CoV-2 with Fluorescence Microscopy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6558.	1.8	15
343	A versatile reverse genetics platform for SARS-CoV-2 and other positive-strand RNA viruses. <i>Nature Communications</i> , 2021, 12, 3431.	5.8	89
344	Epstein-Barr Virus Lytic Replication Induces ACE2 Expression and Enhances SARS-CoV-2 Pseudotyped Virus Entry in Epithelial Cells. <i>Journal of Virology</i> , 2021, 95, e0019221.	1.5	23
345	Functional landscape of SARS-CoV-2 cellular restriction. <i>Molecular Cell</i> , 2021, 81, 2656-2668.e8.	4.5	137
346	Common Variable Immunodeficiency Disorders, T-Cell Responses to SARS-CoV-2 Vaccines, and the Risk of Chronic COVID-19. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 3575-3583.	2.0	41
348	Relating Ventilatory Support and Drug Treatment Strategies to the Fundamental Pathophysiology in COVID-19 Illness. <i>European Medical Journal (Chelmsford, England)</i> , 0, , .	3.0	0
349	Comparison of Residual Pulmonary Abnormalities 3 Months After Discharge in Patients Who Recovered From COVID-19 of Different Severity. <i>Frontiers in Medicine</i> , 2021, 8, 682087.	1.2	16
350	Histopathological features in fatal COVID-19 acute respiratory distress syndrome. <i>Medicina Intensiva (English Edition)</i> , 2021, 45, 261-270.	0.1	4
351	Bespoke regional blocks for axillary sentinel node biopsy. <i>Journal of Plastic, Reconstructive and Aesthetic Surgery</i> , 2021, 74, 2776-2820.	0.5	0
352	Targeting the Conserved Stem Loop 2 Motif in the SARS-CoV-2 Genome. <i>Journal of Virology</i> , 2021, 95, e0066321.	1.5	42
353	SARS-CoV-2 genomic surveillance identifies naturally occurring truncation of ORF7a that limits immune suppression. <i>Cell Reports</i> , 2021, 35, 109197.	2.9	65
354	Distinct clinical and immunological profiles of patients with evidence of SARS-CoV-2 infection in sub-Saharan Africa. <i>Nature Communications</i> , 2021, 12, 3554.	5.8	21
355	Dynamic innate immune response determines susceptibility to SARS-CoV-2 infection and early replication kinetics. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	139
356	SARS-CoV-2-mediated dysregulation of metabolism and autophagy uncovers host-targeting antivirals. <i>Nature Communications</i> , 2021, 12, 3818.	5.8	172
357	Nasal delivery of an IgM offers broad protection from SARS-CoV-2 variants. <i>Nature</i> , 2021, 595, 718-723.	13.7	128

#	ARTICLE	IF	CITATIONS
358	Rapid, reliable, and reproducible cell fusion assay to quantify SARS-Cov-2 spike interaction with hACE2. <i>PLoS Pathogens</i> , 2021, 17, e1009683.	2.1	18
359	Positive no-touch surfaces and undetectable SARS-CoV-2 aerosols in long-term care facilities: An attempt to understand the contributing factors and the importance of timing in air sampling campaigns. <i>American Journal of Infection Control</i> , 2021, 49, 701-706.	1.1	34
360	Human Nasal and Lung Tissues Infected <i>Ex Vivo</i> with SARS-CoV-2 Provide Insights into Differential Tissue-Specific and Virus-Specific Innate Immune Responses in the Upper and Lower Respiratory Tract. <i>Journal of Virology</i> , 2021, 95, e0013021.	1.5	47
362	How and to What Extent Immunological Responses to SARS-CoV-2 Shape Pulmonary Function in COVID-19 Patients. <i>Frontiers in Physiology</i> , 2021, 12, 628288.	1.3	5
363	Stem Cell-derived Respiratory Epithelial Cell Cultures as Human Disease Models. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2021, 64, 657-668.	1.4	7
364	The total number and mass of SARS-CoV-2 virions. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	187
365	Intersubject Variation in ACE2 Protein Expression in Human Airway Epithelia and Its Relationship to Severe Acute Respiratory Syndrome Coronavirus 2. <i>Journal of Infectious Diseases</i> , 2021, 224, 1357-1361.	1.9	3
366	Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants. <i>Science</i> , 2021, 373, .	6.0	174
367	Susceptibility of Well-Differentiated Airway Epithelial Cell Cultures from Domestic and Wild Animals to Severe Acute Respiratory Syndrome Coronavirus 2. <i>Emerging Infectious Diseases</i> , 2021, 27, 1811-1820.	2.0	11
369	THE COVID-19 PANDEMIC IN BRAZIL: A HEALTH AND POTENTIAL WASTE MANAGEMENT CRISIS. , 2021, , 11-13.		1
370	Airway and Alveoli Organoids as Valuable Research Tools in COVID-19. <i>ACS Biomaterials Science and Engineering</i> , 2021, 7, 3487-3502.	2.6	8
371	Contemporary Review of Olfactory Dysfunction in COVID-19. <i>Journal of Rhinology</i> , 2021, 28, 73-80.	0.1	0
372	Simulating near-field enhancement in transmission of airborne viruses with a quadrature-based model. <i>Indoor Air</i> , 2021, 31, 1843-1859.	2.0	10
373	Nasal ciliated cells are primary targets for SARS-CoV-2 replication in the early stage of COVID-19. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	169
375	Expression of SARS-CoV-2 Entry Factors in Human Alveolar Type II Cells in Aging and Emphysema. <i>Biomedicines</i> , 2021, 9, 779.	1.4	3
377	Distinctive features of severe SARS-CoV-2 pneumonia. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	49
378	Keep out! SARS-CoV-2 entry inhibitors: their role and utility as COVID-19 therapeutics. <i>Virology Journal</i> , 2021, 18, 154.	1.4	29
379	Is there really a correlation between viral load and olfactory and gustatory dysfunction?. <i>American Journal of Otolaryngology - Head and Neck Medicine and Surgery</i> , 2021, 42, 103041.	0.6	0

#	ARTICLE	IF	CITATIONS
380	Virucidal and antiviral activity of astodimer sodium against SARS-CoV-2 in vitro. <i>Antiviral Research</i> , 2021, 191, 105089.	1.9	24
381	Impact of inhaled pollutants on response to viral infection in controlled exposures. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 148, 1420-1429.	1.5	22
384	Modulation of ACE-2 mRNA by inflammatory cytokines in human thyroid cells: a pilot study. <i>Endocrine</i> , 2021, 74, 638-645.	1.1	24
385	Perspective of the Relationship between the Susceptibility to Initial SARS-CoV-2 Infectivity and Optimal Nasal Conditioning of Inhaled Air. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7919.	1.8	8
386	Hide and seek in a pandemic: review of SARS-CoV-2 infection and sequelae in children. <i>Experimental Physiology</i> , 2022, 107, 653-664.	0.9	7
387	Reply to Eisenhut. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2021, 321, L287-L289.	1.3	1
388	SARS-CoV-2 infection induces the dedifferentiation of multiciliated cells and impairs mucociliary clearance. <i>Nature Communications</i> , 2021, 12, 4354.	5.8	154
390	SARS-CoV-2: Cross-scale Insights from Ecology and Evolution. <i>Trends in Microbiology</i> , 2021, 29, 593-605.	3.5	12
393	Laboratory Diagnosis of SARS-CoV-2 Pneumonia. <i>Diagnostics</i> , 2021, 11, 1270.	1.3	20
394	Immunological mechanisms of vaccine-induced protection against COVID-19 in humans. <i>Nature Reviews Immunology</i> , 2021, 21, 475-484.	10.6	434
395	Systematic analysis of SARS-CoV-2 infection of an ACE2-negative human airway cell. <i>Cell Reports</i> , 2021, 36, 109364.	2.9	109
396	The Effect of Azithromycin Plus Zinc Sulfate on ACE2 Expression through $\text{p}38^{\beta}$ of Human Respiratory Cells in SARS-CoV-2: In Vitro Study. <i>Covid</i> , 2021, 1, 263-275.	0.7	1
397	Characterization of SARS-CoV-2 and host entry factors distribution in a COVID-19 autopsy series. <i>Communications Medicine</i> , 2021, 1, .	1.9	16
398	Sex Disparities and Neutralizing-Antibody Durability to SARS-CoV-2 Infection in Convalescent Individuals. <i>MSphere</i> , 2021, 6, e0027521.	1.3	36
400	Cellular and Molecular Effects of SARS-CoV-2 Linking Lung Infection to the Brain. <i>Frontiers in Immunology</i> , 2021, 12, 730088.	2.2	12
401	Dynamics of SARS-CoV-2 Spike Proteins in Cell Entry: Control Elements in the Amino-Terminal Domains. <i>MBio</i> , 2021, 12, e0159021.	1.8	49
403	Key Metabolic Enzymes Involved in Remdesivir Activation in Human Lung Cells. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0060221.	1.4	37
404	Adult stem cell-derived complete lung organoid models emulate lung disease in COVID-19. <i>ELife</i> , 2021, 10, .	2.8	64

#	ARTICLE	IF	CITATIONS
405	InÂvitro and inÂvivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies. <i>Cell</i> , 2021, 184, 4203-4219.e32.	13.5	228
406	SARS-CoV-2 Short-Time Infection Produces Relevant Cytopathic Effects in Vero E6 Cell Line. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 9020.	1.2	9
407	Intranasal Corticosteroids Are Associated with Better Outcomes in Coronavirus Disease 2019. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 3934-3940.e9.	2.0	20
408	Current Trends and Research Topics Regarding Intestinal Organoids: An Overview Based on Bibliometrics. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 609452.	1.8	3
410	Human models for COVIDâ€19 research. <i>Journal of Physiology</i> , 2021, 599, 4255-4267.	1.3	7
412	A model of the innate immune response to SARS-CoV-2 in the alveolar epithelium. <i>Royal Society Open Science</i> , 2021, 8, 210090.	1.1	4
413	Temporal omics analysis in Syrian hamsters unravel cellular effector responses to moderate COVID-19. <i>Nature Communications</i> , 2021, 12, 4869.	5.8	68
414	Evidence of SARS-CoV-2 Virus in the Middle Ear of Deceased COVID-19 Patients. <i>Diagnostics</i> , 2021, 11, 1535.	1.3	14
415	Respiratory epithelial cell responses to SARS-CoV-2 in COVID-19. <i>Thorax</i> , 2022, 77, 203-209.	2.7	90
416	Selfâ€infection with speech aerosol may contribute to COVIDâ€19 severity. <i>Journal of Internal Medicine</i> , 2021, 290, 1275-1277.	2.7	6
417	Cell therapy strategies for COVID-19: Current approaches and potential applications. <i>Science Advances</i> , 2021, 7, .	4.7	20
418	Paradoxical effects of cigarette smoke and COPD on SARS-CoV-2 infection and disease. <i>BMC Pulmonary Medicine</i> , 2021, 21, 275.	0.8	9
419	Unfolded Protein Response Inhibition Reduces Middle East Respiratory Syndrome Coronavirus-Induced Acute Lung Injury. <i>MBio</i> , 2021, 12, e0157221.	1.8	16
420	Lectins enhance SARS-CoV-2 infection and influence neutralizing antibodies. <i>Nature</i> , 2021, 598, 342-347.	13.7	230
421	SARS-CoV-2 infection induces beta cell transdifferentiation. <i>Cell Metabolism</i> , 2021, 33, 1577-1591.e7.	7.2	123
422	Differences and similarities between the upper and lower airway: focusing on innate immunity. <i>Rhinology</i> , 2021, 59, 0-0.	0.7	5
423	Computational design of SARS-CoV-2 peptide binders with better predicted binding affinities than human ACE2 receptor. <i>Scientific Reports</i> , 2021, 11, 15650.	1.6	17
426	Single-Dose Intranasal Administration of AdCOVID Elicits Systemic and Mucosal Immunity against SARS-CoV-2 and Fully Protects Mice from Lethal Challenge. <i>Vaccines</i> , 2021, 9, 881.	2.1	86

#	ARTICLE	IF	CITATIONS
427	Modeling Within-Host Dynamics of SARS-CoV-2 Infection: A Case Study in Ferrets. <i>Viruses</i> , 2021, 13, 1635.	1.5	24
428	Longitudinal metabolomics of human plasma reveals prognostic markers of COVID-19 disease severity. <i>Cell Reports Medicine</i> , 2021, 2, 100369.	3.3	61
429	Intracellular Life Cycle Kinetics of SARS-CoV-2 Predicted Using Mathematical Modelling. <i>Viruses</i> , 2021, 13, 1735.	1.5	15
430	Induction of interferon response by high viral loads at early stage infection may protect against severe outcomes in COVID-19 patients. <i>Scientific Reports</i> , 2021, 11, 15715.	1.6	15
431	Characterization of the SARS-CoV-2 Host Response in Primary Human Airway Epithelial Cells from Aged Individuals. <i>Viruses</i> , 2021, 13, 1603.	1.5	11
432	In Vitro Modelling of Respiratory Virus Infections in Human Airway Epithelial Cells – A Systematic Review. <i>Frontiers in Immunology</i> , 2021, 12, 683002.	2.2	28
433	In silico study on spice-derived antiviral phytochemicals against SARS-CoV-2 TMPRSS2 target. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, 40, 11874-11884.	2.0	13
434	Binding and entering: COVID finds a new home. <i>PLoS Pathogens</i> , 2021, 17, e1009857.	2.1	9
435	COVID-19 Immunobiology: Lessons Learned, New Questions Arise. <i>Frontiers in Immunology</i> , 2021, 12, 719023.	2.2	28
436	How to address SARS-CoV-2 airborne transmission to ensure effective protection of healthcare workers? A review of the literature. <i>Infectious Diseases Now</i> , 2021, 51, 410-417.	0.7	3
438	Pre-activated antiviral innate immunity in the upper airways controls early SARS-CoV-2 infection in children. <i>Nature Biotechnology</i> , 2022, 40, 319-324.	9.4	229
439	Repurposable drugs for SARS-CoV-2 and influenza sepsis with scRNA-seq data targeting post-transcription modifications. <i>Precision Clinical Medicine</i> , 2021, 4, 215-230.	1.3	3
441	Age- and airway disease related gene expression patterns of key SARS-CoV-2 entry factors in human nasal epithelia. <i>Virology</i> , 2021, 561, 65-68.	1.1	4
442	The Platelet Role in Severe and Fatal Forms of COVID-19.. <i>Current Molecular Medicine</i> , 2021, 21, .	0.6	2
444	Respiratory Nasal Mucosa in Chronic Rhinosinusitis with Nasal Polyps versus COVID-19: Histopathology, Electron Microscopy Analysis and Assessing of Tissue Interleukin-33. <i>Journal of Clinical Medicine</i> , 2021, 10, 4110.	1.0	10
446	Evaluation of Cell-Based and Surrogate SARS-CoV-2 Neutralization Assays. <i>Journal of Clinical Microbiology</i> , 2021, 59, e0052721.	1.8	71
447	Molecular Communication Theoretical Modeling and Analysis of SARS-CoV2 Transmission in Human Respiratory System. <i>IEEE Transactions on Molecular, Biological, and Multi-Scale Communications</i> , 2021, 7, 153-164.	1.4	14
448	Impaired local intrinsic immunity to SARS-CoV-2 infection in severe COVID-19. <i>Cell</i> , 2021, 184, 4713-4733.e22.	13.5	206

#	ARTICLE	IF	CITATIONS
449	Single-dose intranasal vaccination elicits systemic and mucosal immunity against SARS-CoV-2. <i>IScience</i> , 2021, 24, 103037.	1.9	66
450	Enrichment of SARS-CoV-2 Entry Factors and Interacting Intracellular Genes in Tissue and Circulating Immune Cells. <i>Viruses</i> , 2021, 13, 1757.	1.5	2
453	Longitudinal Analysis of Inflammatory Response to SARS-CoV-2 in the Upper Respiratory Tract Reveals an Association with Viral Load, Independent of Symptoms. <i>Journal of Clinical Immunology</i> , 2021, 41, 1723-1732.	2.0	7
454	Corticosteroid Protection Against COVID-19: Begin with the Nose. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 3941-3943.	2.0	5
455	SARS-CoV-2 Subgenomic RNAs: Characterization, Utility, and Perspectives. <i>Viruses</i> , 2021, 13, 1923.	1.5	38
456	Determinants of SARS-CoV-2 entry and replication in airway mucosal tissue and susceptibility in smokers. <i>Cell Reports Medicine</i> , 2021, 2, 100421.	3.3	11
458	A Bifluorescent-Based Assay for the Identification of Neutralizing Antibodies against SARS-CoV-2 Variants of Concern <i><i>In Vitro</i></i> and <i><i>In Vivo</i></i> . <i>Journal of Virology</i> , 2021, 95, e0112621.	1.5	13
459	Application of Human Induced Pluripotent Stem Cell-Derived Cellular and Organoid Models for COVID-19 Research. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 720099.	1.8	14
460	Neutrophils and lymphopenia, an unknown axis in severe COVID-19 disease. <i>PLoS Pathogens</i> , 2021, 17, e1009850.	2.1	22
461	Protective Efficacy of Rhesus Adenovirus COVID-19 Vaccines against Mouse-Adapted SARS-CoV-2. <i>Journal of Virology</i> , 2021, 95, e0097421.	1.5	12
463	Analysis of SARS-CoV-2 infection dynamic in vivo using reporter-expressing viruses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	25
464	ACE2 in the Gut: The Center of the 2019-nCoV Infected Pathology. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 708336.	1.6	15
465	A hitchhiker's guide through the COVID-19 galaxy. <i>Clinical Immunology</i> , 2021, 232, 108849.	1.4	3
466	A prenylated dsRNA sensor protects against severe COVID-19. <i>Science</i> , 2021, 374, eabj3624.	6.0	124
467	COVID-19 Animal Models and Vaccines: Current Landscape and Future Prospects. <i>Vaccines</i> , 2021, 9, 1082.	2.1	8
468	Multiomics: unraveling the panoramic landscapes of SARS-CoV-2 infection. <i>Cellular and Molecular Immunology</i> , 2021, 18, 2313-2324.	4.8	31
469	SARS-CoV-2 mucosal antibody development and persistence and their relation to viral load and COVID-19 symptoms. <i>Nature Communications</i> , 2021, 12, 5621.	5.8	63
470	The antiviral activity of iota-, kappa-, and lambda-carrageenan against COVID-19: A critical review. <i>Clinical Epidemiology and Global Health</i> , 2021, 12, 100826.	0.9	36

#	ARTICLE	IF	CITATIONS
471	Prediction and control of aerosol transmission of SARS-CoV-2 in ventilated context: from source to receptor. <i>Sustainable Cities and Society</i> , 2022, 76, 103416.	5.1	39
472	Polyphenylene carboxymethylene (PPCM) microbicide repurposed as antiviral against SARS-CoV-2. Proof of concept in primary human undifferentiated epithelial cells. <i>Antiviral Research</i> , 2021, 194, 105162.	1.9	6
473	COVID-19-associated acute respiratory distress syndrome (CARDS): Current knowledge on pathophysiology and ICU treatment – A narrative review. <i>Bailliere's Best Practice and Research in Clinical Anaesthesiology</i> , 2021, 35, 351-368.	1.7	57
474	The circadian clock component BMAL1 regulates SARS-CoV-2 entry and replication in lung epithelial cells. <i>IScience</i> , 2021, 24, 103144.	1.9	34
475	Impact of temperature on the affinity of SARS-CoV-2 Spike glycoprotein for host ACE2. <i>Journal of Biological Chemistry</i> , 2021, 297, 101151.	1.6	42
476	Test, trace, isolate: evidence for declining SARS-CoV-2 PCR sensitivity in a clinical cohort. <i>Diagnostic Microbiology and Infectious Disease</i> , 2021, 101, 115392.	0.8	7
477	An angiotensin-converting enzyme-2-derived heptapeptide GK-7 for SARS-CoV-2 spike blockade. <i>Peptides</i> , 2021, 145, 170638.	1.2	10
478	Mucus targeting as a plausible approach to improve lung function in COVID-19 patients. <i>Medical Hypotheses</i> , 2021, 156, 110680.	0.8	13
479	Airborne magnetic nanoparticles may contribute to COVID-19 outbreak: Relationships in Greece and Iran. <i>Environmental Research</i> , 2022, 204, 112054.	3.7	7
480	COVID-19 Beyond the Lungs. <i>Advances in Medical Diagnosis, Treatment, and Care</i> , 2022, , 109-126.	0.1	0
481	Effects of cigarette smoking on SARS-CoV-2 receptor ACE2 expression in the respiratory epithelium. <i>Journal of Pathology</i> , 2021, 253, 351-354.	2.1	7
482	Mucociliary Respiratory Epithelium Integrity in Molecular Defense and Susceptibility to Pulmonary Viral Infections. <i>Biology</i> , 2021, 10, 95.	1.3	31
483	Clocks, Viruses, and Immunity: Lessons for the COVID-19 Pandemic. <i>Journal of Biological Rhythms</i> , 2021, 36, 23-34.	1.4	28
484	Epigenetic underpinnings of inflammation: Connecting the dots between pulmonary diseases, lung cancer and COVID-19. <i>Seminars in Cancer Biology</i> , 2022, 83, 384-398.	4.3	53
485	An organoid-derived bronchioalveolar model for SARS-CoV-2 infection of human alveolar type II-like cells. <i>EMBO Journal</i> , 2021, 40, e105912.	3.5	153
486	COVID-19 Transmission, Current Treatment, and Future Therapeutic Strategies. <i>Molecular Pharmaceutics</i> , 2021, 18, 754-771.	2.3	193
488	COVID-19, COPD, and AECOPD: Immunological, Epidemiological, and Clinical Aspects. <i>Frontiers in Medicine</i> , 2020, 7, 627278.	1.2	24
489	Transcriptome of nasopharyngeal samples from COVID-19 patients and a comparative analysis with other SARS-CoV-2 infection models reveal disparate host responses against SARS-CoV-2. <i>Journal of Translational Medicine</i> , 2021, 19, 32.	1.8	44

#	ARTICLE	IF	CITATIONS
490	Distinct Disease Severity Between Children and Older Adults With Coronavirus Disease 2019 (COVID-19): Impacts of ACE2 Expression, Distribution, and Lung Progenitor Cells. <i>Clinical Infectious Diseases</i> , 2021, 73, e4154-e4165.	2.9	42
491	Development of a Cell-Based Luciferase Complementation Assay for Identification of SARS-CoV-2 3CLpro Inhibitors. <i>Viruses</i> , 2021, 13, 173.	1.5	37
492	Circuits between infected macrophages and T cells in SARS-CoV-2 pneumonia. <i>Nature</i> , 2021, 590, 635-641.	13.7	524
493	Type I interferon: From innate response to treatment for COVID-19. <i>Pediatric Investigation</i> , 2020, 4, 275-280.	0.6	17
494	Human Monoclonal Antibodies: On the Menu of Targeted Therapeutics Against COVID-19. <i>Virologica Sinica</i> , 2020, 35, 713-724.	1.2	10
495	COVID-19 in clinical practice: A narrative synthesis. <i>Médecine Et Maladies Infectieuses</i> , 2020, 50, 639-647.	5.1	2
496	Biomaterials-Based Opportunities to Engineer the Pulmonary Host Immune Response in COVID-19. <i>ACS Biomaterials Science and Engineering</i> , 2021, 7, 1742-1764.	2.6	16
497	Innate Immunity Plays a Key Role in Controlling Viral Load in COVID-19: Mechanistic Insights from a Whole-Body Infection Dynamics Model. <i>ACS Pharmacology and Translational Science</i> , 2021, 4, 248-265.	2.5	36
498	Discovery and characterization of ACE2 – a 20-year journey of surprises from vasopeptidase to COVID-19. <i>Clinical Science</i> , 2020, 134, 2489-2501.	1.8	16
499	A Pathophysiological Model for COVID-19: Critical Importance of Transepithelial Sodium Transport upon Airway Infection. <i>Function</i> , 2020, 1, zqaa024.	1.1	24
500	Angiotensin-converting enzyme 2: from a vasoactive peptide to the gatekeeper of a global pandemic. <i>Current Opinion in Nephrology and Hypertension</i> , 2021, 30, 252-263.	1.0	7
563	High levels of SARS-CoV-2-specific T cells with restricted functionality in severe courses of COVID-19. <i>JCI Insight</i> , 2020, 5, .	2.3	97
564	On the whereabouts of SARS-CoV-2 in the human body: A systematic review. <i>PLoS Pathogens</i> , 2020, 16, e1009037.	2.1	168
565	Comment on Increased Risk of COVID-19 Among Users of Proton Pump Inhibitors. <i>American Journal of Gastroenterology</i> , 2020, 115, 1921-1921.	0.2	2
566	Can ACE2 expression explain SARS-CoV-2 infection of the respiratory epithelia in COVID-19?. <i>Molecular Systems Biology</i> , 2020, 16, e9841.	3.2	27
570	Single-Dose Intranasal Vaccination Elicits Systemic and Mucosal Immunity Against SARS-CoV-2. <i>SSRN Electronic Journal</i> , 0, , .	0.4	4
571	Nicotine Changes Airway Epithelial Phenotype and May Increase the SARS-COV-2 Infection Severity. <i>Molecules</i> , 2021, 26, 101.	1.7	12
572	Endothelium Infection and Dysregulation by SARS-CoV-2: Evidence and Caveats in COVID-19. <i>Viruses</i> , 2021, 13, 29.	1.5	118

#	ARTICLE	IF	CITATIONS
573	COVID diagnostics: Do we have sufficient armamentarium for the present and the unforeseen?. Indian Journal of Medical Specialities, 2020, 11, 117.	0.1	2
575	ACE2: Evidence of role as entry receptor for SARS-CoV-2 and implications in comorbidities. ELife, 2020, 9, .	2.8	266
576	In Vitro Virucidal Effect of Intranasally Delivered Chlorpheniramine Maleate Compound Against Severe Acute Respiratory Syndrome Coronavirus 2. Cureus, 2020, 12, e10501.	0.2	17
577	Potential Role of Xylitol Plus Grapefruit Seed Extract Nasal Spray Solution in COVID-19: Case Series. Cureus, 2020, 12, e11315.	0.2	18
578	OUP accepted manuscript. Briefings in Functional Genomics, 2021, , .	1.3	2
579	Analysis of Severe Acute Respiratory Syndrome 2 Replication in Explant Cultures of the Human Upper Respiratory Tract Reveals Broad Tissue Tropism of Wild-Type and B.1.1.7 Variant Viruses. Journal of Infectious Diseases, 2021, 224, 2020-2024.	1.9	5
581	Mechanisms of SARS-CoV-2 entry into cells. Nature Reviews Molecular Cell Biology, 2022, 23, 3-20.	16.1	1,532
583	Highly Efficient SARS-CoV-2 Infection of Human Cardiomyocytes: Spike Protein-Mediated Cell Fusion and Its Inhibition. Journal of Virology, 2021, 95, e0136821.	1.5	29
584	How did we get here: what are droplets and aerosols and how far do they go? A historical perspective on the transmission of respiratory infectious diseases. Interface Focus, 2021, 11, 20210049.	1.5	84
585	Replication and single-cycle delivery of SARS-CoV-2 replicons. Science, 2021, 374, 1099-1106.	6.0	49
586	Alveolar Regeneration in COVID-19 Patients: A Network Perspective. International Journal of Molecular Sciences, 2021, 22, 11279.	1.8	7
587	Visible blue light inhibits infection and replication of SARS-CoV-2 at doses that are well-tolerated by human respiratory tissue. Scientific Reports, 2021, 11, 20595.	1.6	15
588	SARS-CoV-2 promotes RIPK1 activation to facilitate viral propagation. Cell Research, 2021, 31, 1230-1243.	5.7	62
590	Determinants of expression of SARS-CoV-2 entry-related genes in upper and lower airways. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 690-694.	2.7	15
591	Mechanisms of Lung Injury Induced by SARS-CoV-2 Infection. Physiology, 2022, 37, 88-100.	1.6	18
592	Development of a highly specific and sensitive VHH-based sandwich immunoassay for the detection of the SARS-CoV-2 nucleoprotein. Journal of Biological Chemistry, 2022, 298, 101290.	1.6	16
593	Infection, Inflammation and Immunity in Covid-19 Infection. Acta Medica Bulgarica, 2021, 48, 77-82.	0.0	0
594	Computational Design of Potent D-Peptide Inhibitors of SARS-CoV-2. Journal of Medicinal Chemistry, 2021, 64, 14955-14967.	2.9	28

#	ARTICLE	IF	CITATIONS
595	Current knowledge about the etiopathogenesis and therapy options for COVID-19. <i>Zdravstvena Zastita</i> , 2020, 49, 43-54.	0.0	2
601	Organoids: a new research model for SARS-CoV-2infection and treatment. <i>Scientia Sinica Vitae</i> , 2023, 53, 238-249.	0.1	1
602	The severity of SARS-CoV-2 infection is dictated by host factors? Epigenetic perspectives. <i>Current Research in Microbial Sciences</i> , 2021, 2, 100079.	1.4	2
604	The History of Methylprednisolone, Ascorbic Acid, Thiamine, and Heparin Protocol and I-MASK+ Ivermectin Protocol for COVID-19. <i>Cureus</i> , 2020, 12, e12403.	0.2	1
607	Features and Interpretation of Olfactory and Gustatory Disorders in the Corona Virus Disease-19. <i>Journal of Physiology & Pathology in Korean Medicine</i> , 2020, 34, 309-318.	0.2	0
608	A Nucleocapsid-based Transcomplementation Cell Culture System of SARS-CoV-2 to Recapitulate the Complete Viral Life Cycle. <i>Bio-protocol</i> , 2021, 11, e4257.	0.2	5
609	SARS-CoV-2 Is a Robot Bioweapon. <i>Advances in Public Policy and Administration</i> , 2022, , 114-164.	0.1	0
610	Rapid field determination of SARS-CoV-2 by a colorimetric and fluorescent dual-functional lateral flow immunoassay biosensor. <i>Sensors and Actuators B: Chemical</i> , 2022, 351, 130897.	4.0	56
611	Mechano-inflammatory sensitivity of ACE2: Implications for the regional distribution of SARS-CoV-2 injury in the lung. <i>Respiratory Physiology and Neurobiology</i> , 2022, 296, 103804.	0.7	3
612	MATH+ and I-MASK+ Protocols for Prevention and Treatment of All Phases of COVID-19 – A Short Review. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
613	Drying of virus-containing particles: modelling effects of droplet origin and composition. <i>Journal of Environmental Health Science & Engineering</i> , 2021, 19, 1987-1996.	1.4	9
615	Pathogenic Basis of Thromboinflammation and Endothelial Injury in COVID-19: Current Findings and Therapeutic Implications. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12081.	1.8	21
616	CCR2 Signaling Restricts SARS-CoV-2 Infection. <i>MBio</i> , 2021, 12, e0274921.	1.8	38
617	Visualizing in deceased COVID-19 patients how SARS-CoV-2 attacks the respiratory and olfactory mucosae but spares the olfactory bulb. <i>Cell</i> , 2021, 184, 5932-5949.e15.	13.5	245
618	Analysis of the effectiveness of face-coverings on the death ratio of COVID-19 using machine learning. <i>Scientific Reports</i> , 2021, 11, 21675.	1.6	4
619	Interferon-Lambda Intranasal Protection and Differential Sex Pathology in a Murine Model of SARS-CoV-2 Infection. <i>MBio</i> , 2021, 12, e0275621.	1.8	21
620	SARS-CoV-2 can infect and propagate in human placenta explants. <i>Cell Reports Medicine</i> , 2021, 2, 100456.	3.3	29
621	Establishment of human distal lung organoids for SARS-CoV-2 infection. <i>Cell Discovery</i> , 2021, 7, 108.	3.1	14

#	ARTICLE	IF	CITATIONS
622	Engineering Preclinical Tools and Therapeutics to Understand and Treat COVID-19. Delaware Journal of Public Health, 2020, 6, 32-35.	0.2	0
628	Overview of the immune response against SARS-CoV-2. , 2022, , 95-113.		0
629	Public health and management. , 2022, , 1-40.		1
631	Receptome profiling identifies KREMEN1 and ASGR1 as alternative functional receptors of SARS-CoV-2. Cell Research, 2022, 32, 24-37.	5.7	98
632	Pleural Mesothelial Cells Modulate the Inflammatory/Profibrotic Response During SARS-CoV-2 Infection. Frontiers in Molecular Biosciences, 2021, 8, 752616.	1.6	6
633	Age-Related Expression of IFN- γ 1 Versus IFN-I and Beta-Defensins in the Nasopharynx of SARS-CoV-2-Infected Individuals. Frontiers in Immunology, 2021, 12, 750279.	2.2	17
634	COVID-19 Infections and Asthma. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 658-663.	2.0	19
635	Reopening the Bavarian State Opera Safely: Hygiene Strategies and Incidence of COVID-19 in Artistic Staff During Theater Season 2020/2021. Journal of Voice, 2021, , .	0.6	2
636	Meteorin- β /Meteorin like/IL-41 attenuates airway inflammation in house dust mite-induced allergic asthma. Cellular and Molecular Immunology, 2022, 19, 245-259.	4.8	15
637	Phosphatidylserine receptors enhance SARS-CoV-2 infection. PLoS Pathogens, 2021, 17, e1009743.	2.1	55
638	Complexity of immune responses in COVID-19. Seminars in Immunology, 2021, 55, 101545.	2.7	10
639	Control of airborne infectious disease in buildings: Evidence and research priorities. Indoor Air, 2022, 32, .	2.0	14
640	Nasal therapyâ€”The missing link in optimising strategies to improve prevention and treatment of COVID-19. PLoS Pathogens, 2021, 17, e1010079.	2.1	10
641	Effects of hypertonic alkaline nasal irrigation on COVID-19. Laryngoscope Investigative Otolaryngology, 2021, 6, 1240-1247.	0.6	8
642	Ecology, evolution and spillover of coronaviruses from bats. Nature Reviews Microbiology, 2022, 20, 299-314.	13.6	108
643	Comments on â€œAn airway organoid-based screen identifies a role for the HIF1 β glycolysis axis in SARS-CoV-2 infectionâ€™. Journal of Molecular Cell Biology, 2021, , .	1.5	1
644	Reverse Genetics with a Full-length Infectious cDNA Clone of Bovine Torovirus. Journal of Virology, 2021, , JVI0156121.	1.5	4
645	Enhanced protective immunity against SARS-CoV-2 elicited by a VSV vector expressing a chimeric spike protein. Signal Transduction and Targeted Therapy, 2021, 6, 389.	7.1	21

#	ARTICLE	IF	CITATIONS
646	Hamster models of COVID-19 pneumonia reviewed: How human can they be?. <i>Veterinary Pathology</i> , 2022, 59, 528-545.	0.8	49
647	Epigenetic glycosylation of SARS-CoV-2 impact viral infection through DC&L-SIGN receptors. <i>IScience</i> , 2021, 24, 103426.	1.9	8
648	An upper bound on one-to-one exposure to infectious human respiratory particles. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	87
649	Roles of antiviral sensing and type I interferon signaling in the restriction of SARS-CoV-2 replication. <i>IScience</i> , 2021, , 103553.	1.9	5
650	Vaccines and Antiviral Developments for SARS-CoV-2 in the Emergence of the COVID-19 Pandemic. <i>RSC Drug Discovery Series</i> , 2021, , 45-60.	0.2	0
651	Anosmia in COVID-19: Underlying Mechanisms and Assessment of an Olfactory Route to Brain Infection (Russian translation). <i>Juvenis Scientia</i> , 2021, 7, 28-59.	0.1	1
652	The Interaction Between Pulmonary Fibrosis and COVID-19 and the Application of Related Anti-Fibrotic Drugs. <i>Frontiers in Pharmacology</i> , 2021, 12, 805535.	1.6	19
653	Planar organization of airway epithelial cell morphology using hydrogel grooves during ciliogenesis fails to induce ciliary alignment. <i>Biomaterials Science</i> , 2022, 10, 396-409.	2.6	1
654	ACE2-IgG1 fusions with improved inÂvitro and inÂvivo activity against SARS-CoV-2. <i>IScience</i> , 2022, 25, 103670.	1.9	29
655	Interacciones entre SARS-CoV-2 y el sistema de defensas del aparato respiratorio: consideraciones para la prevenciÃ³n y el manejo de las infecciones. <i>Ciencia, TecnologÃa Y Salud</i> , 2020, 7, 289-308.	0.0	0
656	Management of Hypertension in Patients with COVID-19: Implication of Angiotensin-Converting Enzyme 2. <i>Cardiology Plus</i> , 2021, 6, 210-217.	0.2	1
657	Single-cell transcriptomics of lung organoids. <i>Organoid</i> , 0, 1, e9.	0.0	0
658	Cellular metabolic basis of altered immunity in the lungs of patients with COVID-19. <i>Medical Microbiology and Immunology</i> , 2022, 211, 49-69.	2.6	13
659	Evaluation of SARS-CoV-2 entry, inflammation and new therapeutics in human lung tissue cells. <i>PLoS Pathogens</i> , 2022, 18, e1010171.	2.1	18
660	Thiol-based chemical probes exhibit antiviral activity against SARS-CoV-2 via allosteric disulfide disruption in the spike glycoprotein. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	28
661	Extracellular vimentin is an attachment factor that facilitates SARS-CoV-2 entry into human endothelial cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	75
662	Human genetic risk of treatment with antiviral nucleoside analog drugs that induce lethal mutagenesis: the special case of molnupiravir. <i>Environmental and Molecular Mutagenesis</i> , 2022, 63, 37-63.	0.9	39
663	Type III CRISPR-based RNA editing for programmable control of SARS-CoV-2 and human coronaviruses. <i>Nucleic Acids Research</i> , 2022, 50, e47-e47.	6.5	8

#	ARTICLE	IF	CITATIONS
664	SARS-CoV-2 Virology. Infectious Disease Clinics of North America, 2022, 36, 251-265.	1.9	7
665	Human Nasal Epithelial Cells Sustain Persistent SARS-CoV-2 Infection <i>In Vitro</i> , despite Eliciting a Prolonged Antiviral Response. MBio, 2022, 13, e0343621.	1.8	12
666	Assessing the risk of vaccine-driven virulence evolution in SARS-CoV-2. Royal Society Open Science, 2022, 9, 211021.	1.1	8
667	Increased small particle aerosol transmission of B.1.1.7 compared with SARS-CoV-2 lineage A in vivo. Nature Microbiology, 2022, 7, 213-223.	5.9	45
668	Non-immune Prophylaxis Against COVID-19 by Targeting Tolerance for Angiotensin II-Triggered SARS-CoV-2 Pathogenesis. Frontiers in Medicine, 2021, 8, 776903.	1.2	1
669	Interrupting aerosol spread and nasal acquisition of SARS-CoV-2 with topical trichloroacetic acid. Italian Journal of Dermatology and Venereology, 2022, 156, 637-641.	0.1	0
670	From SARS-CoV-2 infection to COVID-19 morbidity: an in silico projection of virion flow rates to the lower airway via nasopharyngeal fluid boluses. Rhinology, 2022, 5, 10-18.	0.2	4
671	Immune-Guided Therapy of COVID-19. Cancer Immunology Research, 2022, 10, 384-402.	1.6	20
672	Transmission of Respiratory Viral Diseases to Health Care Workers: COVID-19 as an Example. Annual Review of Public Health, 2022, 43, 311-330.	7.6	14
674	Human airway lineages derived from pluripotent stem cells reveal the epithelial responses to SARS-CoV-2 infection. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2022, 322, L462-L478.	1.3	17
676	Ex Vivo and in Vivo suppression of SARS-CoV-2 with combinatorial AAV/RNAi expression vectors. Molecular Therapy, 2022, 30, 2005-2023.	3.7	10
678	Pharmacokinetic-based failure of a detergent virucidal for severe acute respiratory syndrome "coronavirus" (SARS-CoV-2) nasal infections: A preclinical study and randomized controlled trial. International Forum of Allergy and Rhinology, 2022, , .	1.5	4
679	Cetylpyridinium chloride promotes disaggregation of SARS-CoV-2 virus-like particles. Journal of Oral Microbiology, 2022, 14, 2030094.	1.2	16
681	Vitamin D regulation of immune function during covid-19. Reviews in Endocrine and Metabolic Disorders, 2022, 23, 279-285.	2.6	23
682	A recombinant adenoviral vector with a specific tropism to CD4-positive cells: a new tool for HIV-1 inhibition. Drug Delivery and Translational Research, 2022, 12, 2561-2568.	3.0	1
683	JIB-04 Has Broad-Spectrum Antiviral Activity and Inhibits SARS-CoV-2 Replication and Coronavirus Pathogenesis. MBio, 2022, 13, e0337721.	1.8	14
684	Is the epithelial barrier hypothesis the key to understanding the higher incidence and excess mortality during COVID-19 pandemic? The case of Northern Italy. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 1408-1417.	2.7	13
685	Physiology and pathophysiology of human airway mucus. Physiological Reviews, 2022, 102, 1757-1836.	13.1	78

#	ARTICLE	IF	CITATIONS
686	Air-Liquid-Interface Differentiated Human Nose Epithelium: A Robust Primary Tissue Culture Model of SARS-CoV-2 Infection. <i>International Journal of Molecular Sciences</i> , 2022, 23, 835.	1.8	15
687	Versatile SARS-CoV-2 Reverse-Genetics Systems for the Study of Antiviral Resistance and Replication. <i>Viruses</i> , 2022, 14, 172.	1.5	18
688	Tissue-level alveolar epithelium model for recapitulating SARS-CoV-2 infection and cellular plasticity. <i>Communications Biology</i> , 2022, 5, 70.	2.0	6
689	A guide to immunotherapy for COVID-19. <i>Nature Medicine</i> , 2022, 28, 39-50.	15.2	206
692	Stable Cell Clones Harboring Self-Replicating SARS-CoV-2 RNAs for Drug Screen. <i>Journal of Virology</i> , 2022, 96, jvi0221621.	1.5	14
695	Systems analysis shows that thermodynamic physiological and pharmacological fundamentals drive COVID-19 and response to treatment. <i>Pharmacology Research and Perspectives</i> , 2022, 10, e00922.	1.1	20
696	Topical TMPRSS2 inhibition prevents SARS-CoV-2 infection in differentiated human airway cultures. <i>Life Science Alliance</i> , 2022, 5, e202101116.	1.3	10
697	SARS-CoV-2 Infection and Lung Regeneration. <i>Clinical Microbiology Reviews</i> , 2022, 35, e0018821.	5.7	24
698	Pathological sequelae of long-haul COVID. <i>Nature Immunology</i> , 2022, 23, 194-202.	7.0	408
700	Human Organoids and Organ-on-a-Chips for Addressing COVID-19 Challenges. <i>Advanced Science</i> , 2022, 9, e2105187.	5.6	19
701	Woodsmoke particle exposure prior to SARS-CoV-2 infection alters antiviral response gene expression in human nasal epithelial cells in a sex-dependent manner. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2022, 322, L479-L494.	1.3	10
703	Renin-angiotensin system blockade on angiotensin-converting enzyme 2 and TMPRSS2 in human type II pneumocytes. <i>Life Sciences</i> , 2022, 293, 120324.	2.0	6
704	COVID-19 is a natural infectious disease. <i>Journal of Biosafety and Biosecurity</i> , 2022, 4, 38-42.	1.4	1
705	Dapsone: A Century-Old Medicine and a New Hope for Severe COVID-19. <i>Advances in Infectious Diseases</i> , 2022, 12, 50-56.	0.0	1
706	Controlling the Burden of COVID-19 by Manipulating Host Metabolism. <i>Viral Immunology</i> , 2022, 35, 24-32.	0.6	7
707	Review of human pegivirus: Prevalence, transmission, pathogenesis, and clinical implication. <i>Virulence</i> , 2022, 13, 323-340.	1.8	20
710	Molecular iodine is not responsible for cytotoxicity in iodophors. <i>Journal of Hospital Infection</i> , 2022, 122, 194-202.	1.4	6
711	Pyrimidine inhibitors synergize with nucleoside analogues to block SARS-CoV-2. <i>Nature</i> , 2022, 604, 134-140.	13.7	108

#	ARTICLE	IF	CITATIONS
712	Comparison of SARS-CoV-2 Evolution in Paediatric Primary Airway Epithelial Cell Cultures Compared with Vero-Derived Cell Lines. <i>Viruses</i> , 2022, 14, 325.	1.5	5
713	Subcellular Detection of SARS-CoV-2 RNA in Human Tissue Reveals Distinct Localization in Alveolar Type 2 Pneumocytes and Alveolar Macrophages. <i>MBio</i> , 2022, 13, e0375121.	1.8	18
714	Extracellular Vimentin as a Target Against SARS-CoV-2 Host Cell Invasion. <i>Small</i> , 2022, 18, e2105640.	5.2	41
715	The OM-85 bacterial lysate inhibits SARS-CoV-2 infection of epithelial cells by downregulating SARS-CoV-2 receptor expression. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 923-933.e6.	1.5	17
716	Using thermodynamic equilibrium models to predict the effect of antiviral agents on infectivity: Theoretical application to SARS-CoV-2 and other viruses.. <i>Microbial Risk Analysis</i> , 2022, 21, 100198.	1.3	17
717	Delayed induction of type I and III interferons mediates nasal epithelial cell permissiveness to SARS-CoV-2. <i>Nature Communications</i> , 2021, 12, 7092.	5.8	65
718	Molecular basis of immune evasion by the Delta and Kappa SARS-CoV-2 variants. <i>Science</i> , 2021, 374, 1621-1626.	6.0	232
719	Interactions of Renin-Angiotensin System and COVID-19: The Importance of Daily Rhythms in ACE2, ADAM17 and TMPRSS2 Expression. <i>Physiological Research</i> , 2021, 70, S177-S194.	0.4	14
720	Reinventing positive-strand RNA virus reverse genetics. <i>Advances in Virus Research</i> , 2022, , 1-29.	0.9	4
721	Immune response and potential therapeutic strategies for the SARS-CoV-2 associated with the COVID-19 pandemic. <i>International Journal of Biological Sciences</i> , 2022, 18, 1865-1877.	2.6	6
722	A call for a new perspective in social work and health care: the developmental-clinical social work perspective. COVID-19 pandemic through the human rights perspective. <i>Social Work in Health Care</i> , 2022, 61, 15-35.	0.8	0
726	Targeting the Ubiquitylation and ISGylation Machinery for the Treatment of COVID-19. <i>Biomolecules</i> , 2022, 12, 300.	1.8	11
727	SARS-CoV-2 and Smoker's Paradox: Mediation by Ciliary Beat Frequency and Mucociliary Clearance?. <i>BioMed</i> , 2022, 2, 88-93.	0.6	3
730	The battle between host and SARS-CoV-2: Innate immunity and viral evasion strategies. <i>Molecular Therapy</i> , 2022, 30, 1869-1884.	3.7	36
731	COVID-19 and the Vasculature: Current Aspects and Long-Term Consequences. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 824851.	1.8	51
732	Coping With Stress: The Mitokine GDF-15 as a Biomarker of COVID-19 Severity. <i>Frontiers in Immunology</i> , 2022, 13, 820350.	2.2	22
733	SARS-CoV-2 Infection Triggers Phosphorylation: Potential Target for Anti-COVID-19 Therapeutics. <i>Frontiers in Immunology</i> , 2022, 13, 829474.	2.2	23
734	Commentary: Crossing the Rubicon" pre-emptive recipient bilateral pneumonectomy and delayed lung transplantation. <i>JTCVS Techniques</i> , 2022, , .	0.2	0

#	ARTICLE	IF	CITATIONS
736	Programmed cell death: the pathways to severe COVID-19?. <i>Biochemical Journal</i> , 2022, 479, 609-628.	1.7	30
739	Protease-anti-protease compartmentalization in SARS-CoV-2 ARDS: Therapeutic implications. <i>EBioMedicine</i> , 2022, 77, 103894.	2.7	12
740	Salivary ACE2 and TMPRSS2 link to periodontal status and metabolic parameters. <i>Clinical and Translational Discovery</i> , 2022, 2, .	0.2	4
741	Defining the risk of SARS-CoV-2 variants on immune protection. <i>Nature</i> , 2022, 605, 640-652.	13.7	117
742	Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults. <i>Nature Medicine</i> , 2022, 28, 1031-1041.	15.2	281
743	Impact of vitamin D level and supplementation on systemic lupus erythematosus patients during COVID-19 pandemic. <i>Archives of Rheumatology</i> , 2022, 37, 288-299.	0.3	2
744	Organoid Models of SARS-CoV-2 Infection: What Have We Learned about COVID-19?. <i>Organoids</i> , 2022, 1, 2-27.	1.8	12
745	COVID-19 symptoms are reduced by targeted hydration of the nose, larynx and trachea. <i>Scientific Reports</i> , 2022, 12, 4599.	1.6	15
746	Human Multi-Compartment Airways-on-Chip Platform for Emulating Respiratory Airborne Transmission: From Nose to Pulmonary Acini. <i>Frontiers in Physiology</i> , 2022, 13, 853317.	1.3	15
747	Ultrastructural insight into SARS-CoV-2 entry and budding in human airway epithelium. <i>Nature Communications</i> , 2022, 13, 1609.	5.8	24
748	SARS-CoV-2 infection of airway cells causes intense viral and cell shedding, two spreading mechanisms affected by IL-13. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, e2119680119.	3.3	53
749	Therapeutic treatment with an oral prodrug of the remdesivir parental nucleoside is protective against SARS-CoV-2 pathogenesis in mice. <i>Science Translational Medicine</i> , 2022, 14, eabm3410.	5.8	49
750	Oral and intranasal vaccines against SARS-CoV-2: Current progress, prospects, advantages, and challenges. <i>Immunity, Inflammation and Disease</i> , 2022, 10, e604.	1.3	29
751	ACE2 protein expression in lung tissues of severe COVID-19 infection. <i>Scientific Reports</i> , 2022, 12, 4058.	1.6	42
752	Postextubation Stridor in Severe COVID-19. <i>Respiratory Care</i> , 2022, 67, 638-646.	0.8	2
754	Airway models in a pandemic: Suitability of models in modeling SARS-CoV-2. <i>PLoS Pathogens</i> , 2022, 18, e1010432.	2.1	1
755	A simple reverse genetics method to generate recombinant coronaviruses. <i>EMBO Reports</i> , 2022, 23, e53820.	2.0	15
756	Antiviral activity of plant juices and green tea against SARS-CoV-2 and influenza virus. <i>Phytotherapy Research</i> , 2022, 36, 2109-2115.	2.8	17

#	ARTICLE	IF	CITATIONS
757	Human Close Contact Behavior-Based Interventions for COVID-19 Transmission. <i>Buildings</i> , 2022, 12, 365.	1.4	7
758	SARS-CoV-2 pathogenesis. <i>Nature Reviews Microbiology</i> , 2022, 20, 270-284.	13.6	404
759	Systematic Tracing of Susceptible Animals to SARS-CoV-2 by a Bioinformatics Framework. <i>Frontiers in Microbiology</i> , 2022, 13, 781770.	1.5	4
760	Single cell atlas of developing mouse dental germs reveals populations of CD24+ and Plac8+ odontogenic cells. <i>Science Bulletin</i> , 2022, 67, 1154-1169.	4.3	9
762	Ultrastructural examination of lung cryobiopsies from a series of fatal COVID-19 cases hardly revealed infected cells. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2022, 480, 967-977.	1.4	6
763	Molecular Virology of SARS-CoV-2 and Related Coronaviruses. <i>Microbiology and Molecular Biology Reviews</i> , 2022, 86, e0002621.	2.9	22
764	Human Organotypic Airway and Lung Organoid Cells of Bronchiolar and Alveolar Differentiation Are Permissive to Infection by Influenza and SARS-CoV-2 Respiratory Virus. <i>Frontiers in Cellular and Infection Microbiology</i> , 2022, 12, 841447.	1.8	17
765	SARS-CoV-2, SARS-CoV, and MERS-CoV encode circular RNAs of spliceosome-independent origin. <i>Journal of Medical Virology</i> , 2022, 94, 3203-3222.	2.5	17
766	Organ manifestations of COVID-19: what have we learned so far (not only) from autopsies?. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2022, 481, 139-159.	1.4	28
767	Expression of ACE2 a Key SARS-CoV-2 Entry Factor Is Not Increased in the Nasal Mucosa of People with Cystic Fibrosis. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2022, 67, 132-137.	1.4	2
768	Impact of SARS-CoV-2 on Host Factors Involved in Mental Disorders. <i>Frontiers in Microbiology</i> , 2022, 13, 845559.	1.5	5
769	Two Different Therapeutic Approaches for SARS-CoV-2 in hiPSCs-Derived Lung Organoids. <i>Cells</i> , 2022, 11, 1235.	1.8	21
770	SARS-CoV-2 Infection Induces Ferroptosis of Sinoatrial Node Pacemaker Cells. <i>Circulation Research</i> , 2022, 130, 963-977.	2.0	49
771	Reverse genetics systems for SARS-CoV-2. <i>Journal of Medical Virology</i> , 2022, 94, 3017-3031.	2.5	17
772	Generation of human tonsil epithelial organoids as an ex vivo model for SARS-CoV-2 infection. <i>Biomaterials</i> , 2022, 283, 121460.	5.7	14
773	Modeling insights into SARS-CoV-2 respiratory tract infections prior to immune protection. <i>Biophysical Journal</i> , 2022, 121, 1619-1631.	0.2	17
774	Human organoid models to study SARS-CoV-2 infection. <i>Nature Methods</i> , 2022, 19, 418-428.	9.0	73
775	Dual targeting powder formulation of antiviral agent for customizable nasal and lung deposition profile through single intranasal administration. <i>International Journal of Pharmaceutics</i> , 2022, 619, 121704.	2.6	6

#	ARTICLE	IF	CITATIONS
776	The accessible promoter-mediated supplementary effect of host factors provides new insight into the tropism of SARS-CoV-2. <i>Molecular Therapy - Nucleic Acids</i> , 2022, 28, 249-258.	2.3	2
777	The pH Dependence of Niclosamide Solubility, Dissolution, and Morphology: Motivation for Potentially Universal Mucin-Penetrating Nasal and Throat Sprays for COVID19, its Variants and other Viral Infections. <i>Pharmaceutical Research</i> , 2022, 39, 115-141.	1.7	11
778	Country-level factors dynamics and ABO/Rh blood groups contribution to COVID-19 mortality. <i>Scientific Reports</i> , 2021, 11, 24527.	1.6	4
780	Channels and Transporters of the Pulmonary Lamellar Body in Health and Disease. <i>Cells</i> , 2022, 11, 45.	1.8	5
781	Flagellin From <i>Pseudomonas aeruginosa</i> Modulates SARS-CoV-2 Infectivity in Cystic Fibrosis Airway Epithelial Cells by Increasing TMPRSS2 Expression. <i>Frontiers in Immunology</i> , 2021, 12, 714027.	2.2	9
782	An Evaluation of YouTube Videos as a Surgical Instructional Tool for Endoscopic Endonasal Approaches in Otolaryngology. <i>Ear, Nose and Throat Journal</i> , 2021, , 014556132110624.	0.4	8
788	Understanding and Managing Severe Asthma in the Context of COVID-19. <i>ImmunoTargets and Therapy</i> , 2021, Volume 10, 419-430.	2.7	1
789	An update on host immunity correlates and prospects of re-infection in COVID-19. <i>International Reviews of Immunology</i> , 2022, 41, 367-392.	1.5	9
790	SARS-CoV-2 Infection and Pancreatic Î² Cell Failure. <i>Biology</i> , 2022, 11, 22.	1.3	15
791	Iota-Carrageenan Inhibits Replication of SARS-CoV-2 and the Respective Variants of Concern Alpha, Beta, Gamma and Delta. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13202.	1.8	20
793	Indoor aerosol science aspects of SARS-CoV-2 transmission. <i>Indoor Air</i> , 2022, 32, .	2.0	36
794	Facile discovery of surrogate cytokine agonists. <i>Cell</i> , 2022, 185, 1414-1430.e19.	13.5	33
796	Identification of Transcription Factors Regulating SARS-CoV-2 Tropism Factor Expression by Inferring Cell-Type-Specific Transcriptional Regulatory Networks in Human Lungs. <i>Viruses</i> , 2022, 14, 837.	1.5	3
797	Aerosol exposure of staff during dental treatments: a model study. <i>BMC Oral Health</i> , 2022, 22, 128.	0.8	8
799	Nanomaterials and metal-organic frameworks for biosensing applications of mutations of the emerging viruses. <i>Analytical Biochemistry</i> , 2022, 648, 114680.	1.1	11
800	Immunonutrition and SARS-CoV-2 Infection in Children with Obesity. <i>Nutrients</i> , 2022, 14, 1701.	1.7	6
804	Immune and epithelial determinants of age-related risk and alveolar injury in fatal COVID-19. <i>JCI Insight</i> , 2022, 7, .	2.3	2
805	ACE2 and COVID-19 Susceptibility and Severity. , 2022, 13, 360.		18

#	ARTICLE	IF	CITATIONS
807	Long-read 16S-seq reveals nasopharynx microbial dysbiosis and enrichment of <i>Mycobacterium</i> and <i>Mycoplasma</i> in COVID-19 patients: a potential source of co-infection. <i>Molecular Omics</i> , 2022, 18, 490-505.	1.4	5
809	Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants. <i>BioDrugs</i> , 2022, 36, 231-323.	2.2	24
811	Daily longitudinal sampling of SARS-CoV-2 infection reveals substantial heterogeneity in infectiousness. <i>Nature Microbiology</i> , 2022, 7, 640-652.	5.9	99
813	New endemic and pandemic pathologies with interhuman airborne transmission through ear, nose and throat anatomical sites. <i>Acta Otorhinolaryngologica Italica</i> , 2022, 42, S5-S13.	0.7	6
814	Function of epithelial stem cell in the repair of alveolar injury. <i>Stem Cell Research and Therapy</i> , 2022, 13, 170.	2.4	8
815	OVASO : Integrated binary CNN models to classify COVID-19, pneumonia and healthy lung in X-ray images. <i>International Journal of Imaging Systems and Technology</i> , 0, , .	2.7	2
816	Susceptibility of Patients with Airway Disease to SARS-CoV-2 Infection. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 206, 696-703.	2.5	6
819	Toll-like receptor-agonist-based therapies for respiratory viral diseases: thinking outside the cell. <i>European Respiratory Review</i> , 2022, 31, 210274.	3.0	9
820	Nanoformulated Remdesivir with Extremely Low Content of Poly(2-Coxazoline)-Based Stabilizer for Aerosol Treatment of COVID-19. <i>Macromolecular Bioscience</i> , 2022, 22, e2200056.	2.1	6
821	Rationale for 1068 nm Photobiomodulation Therapy (PBMT) as a Novel, Non-Invasive Treatment for COVID-19 and Other Coronaviruses: Roles of NO and Hsp70. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5221.	1.8	9
822	Vitamin D Regulation of Immune Function. <i>Current Osteoporosis Reports</i> , 2022, 20, 186-193.	1.5	30
823	Post COVID-19 Condition in Children and Adolescents: An Emerging Problem. <i>Frontiers in Pediatrics</i> , 2022, 10, .	0.9	39
824	The clinical impact of maternal COVID-19 on mothers, their infants, and placentas with an analysis of vertical transfer of maternal SARS-CoV-2-specific IgG antibodies. <i>Placenta</i> , 2022, 123, 12-23.	0.7	13
825	Headache and cognitive disturbance correlate with ganglion cell layer thickness in patients who recovered from COVID-19. <i>Clinical Neurology and Neurosurgery</i> , 2022, 217, 107263.	0.6	4
826	Efficacy of the Sentinox Spray in Reducing Viral Load in Mild COVID-19 and Its Virucidal Activity against Other Respiratory Viruses: Results of a Randomized Controlled Trial and an In Vitro Study. <i>Viruses</i> , 2022, 14, 1033.	1.5	3
827	Why do some coronaviruses become pandemic threats when others do not?. <i>PLoS Biology</i> , 2022, 20, e3001652.	2.6	3
828	The STING Ligand and Delivery System Synergistically Enhance the Immunogenicity of an Intranasal Spike SARS-CoV-2 Vaccine Candidate. <i>Biomedicines</i> , 2022, 10, 1142.	1.4	5
829	Endomembrane remodeling in SARS-CoV-2 infection. , 2022, 1, 100031.		12

#	ARTICLE	IF	CITATIONS
830	Repurposing povidone-iodine to reduce the risk of SARS-CoV-2 infection and transmission: a narrative review. <i>Annals of Medicine</i> , 2022, 54, 1488-1499.	1.5	15
831	Ethnoracial Disparities in SARS-CoV-2 Seroprevalence in a Large Cohort of Individuals in Central North Carolina from April to December 2020. <i>MSphere</i> , 2022, 7, e0084121.	1.3	6
834	SARS-CoV-2 ORF7a potently inhibits the antiviral effect of the host factor SERINC5. <i>Nature Communications</i> , 2022, 13, .	5.8	32

835

#	ARTICLE	IF	CITATIONS
852	Immunofluorescence-Mediated Detection of Respiratory Virus Infections in Human Airway Epithelial Cultures. <i>Current Protocols</i> , 2022, 2, .	1.3	3
853	The Potential of Purinergic Signaling to Thwart Viruses Including SARS-CoV-2. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
854	Characteristic patterns of SARS-CoV-2 on chest CT suggests a hematologic pathway for viral entry into the lung. <i>Clinical Imaging</i> , 2022, , .	0.8	1
855	Intranasal immunization with a proteosome-adjuvanted SARS-CoV-2 spike protein-based vaccine is immunogenic and efficacious in mice and hamsters. <i>Scientific Reports</i> , 2022, 12, .	1.6	13
856	Olfactory dysfunction in COVID-19: pathology and long-term implications for brain health. <i>Trends in Molecular Medicine</i> , 2022, 28, 781-794.	3.5	33
857	Nasal and Parotid Blood Pool Activity Is Significantly Correlated with Metabolic Syndrome Components and Sleep Apnea. <i>Metabolic Syndrome and Related Disorders</i> , 0, , .	0.5	1
858	Hybrid measurement of respiratory aerosol reveals a dominant coarse fraction resulting from speech that remains airborne for minutes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	17
859	Host Kinase CSNK2 is a Target for Inhibition of Pathogenic SARS-like β -Coronaviruses. <i>ACS Chemical Biology</i> , 2022, 17, 1937-1950.	1.6	16
860	A close shave: How SARS-CoV-2 induces the loss of cilia. <i>Journal of Cell Biology</i> , 2022, 221, .	2.3	0
861	A bipotential organoid model of respiratory epithelium recapitulates high infectivity of SARS-CoV-2 Omicron variant. <i>Cell Discovery</i> , 2022, 8, .	3.1	28
862	Preferential uptake of SARS-CoV-2 by pericytes potentiates vascular damage and permeability in an organoid model of the microvasculature. <i>Cardiovascular Research</i> , 2022, 118, 3085-3096.	1.8	17
863	Aerosol Transport Modeling: The Key Link Between Lung Infections of Individuals and Populations. <i>Frontiers in Physiology</i> , 0, 13, .	1.3	12
864	Bioluminescent and Fluorescent Reporter-Expressing Recombinant SARS-CoV-2. <i>Methods in Molecular Biology</i> , 2022, , 235-248.	0.4	3
865	Experimental Models of SARS-COV-2 Infection in the Central Nervous System. <i>Journal of Central Nervous System Disease</i> , 2022, 14, 117957352211022.	0.7	0
867	COVID-19 and dementia; Hard to forget yet haunting forgetfulness!. <i>Annals of Indian Academy of Neurology</i> , 2022, 25, 832.	0.2	0
868	3D Human Organoids: The Next "Viral" Model for the Molecular Basis of Infectious Diseases. <i>Biomedicines</i> , 2022, 10, 1541.	1.4	6
869	Tissue immunity to SARS-CoV-2: Role in protection and immunopathology*. <i>Immunological Reviews</i> , 2022, 309, 25-39.	2.8	11
871	Distinct airway epithelial immune responses after infection with SARS-CoV-2 compared to H1N1. <i>Mucosal Immunology</i> , 2022, 15, 952-963.	2.7	15

#	ARTICLE	IF	CITATIONS
872	Virus Infection and Systemic Inflammation: Lessons Learnt from COVID-19 and Beyond. <i>Cells</i> , 2022, 11, 2198.	1.8	9
873	Peptidomimetic inhibitors of TMPRSS2 block SARS-CoV-2 infection in cell culture. <i>Communications Biology</i> , 2022, 5, .	2.0	6
874	Cell and Animal Models for SARS-CoV-2 Research. <i>Viruses</i> , 2022, 14, 1507.	1.5	9
875	Hypertonic Saline Use and Traditional Nasal Irrigation: A Possible Preventative Measure against COVID-19. <i>Journal of Contemporary Dental Practice</i> , 2022, 23, 379-382.	0.2	2
876	Changes in Symptoms Experienced by SARS-CoV-2-Infected Individuals “ From the First Wave to the Omicron Variant. <i>Frontiers in Virology</i> , 0, 2, .	0.7	20
878	Goblet Cell Hyperplasia Increases SARS-CoV-2 Infection in Chronic Obstructive Pulmonary Disease. <i>Microbiology Spectrum</i> , 2022, 10, .	1.2	14
879	SARS-CoV-2 Achieves Immune Escape by Destroying Mitochondrial Quality: Comprehensive Analysis of the Cellular Landscapes of Lung and Blood Specimens From Patients With COVID-19. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	16
880	Whole-genome analysis and mutation pattern of SARS-CoV-2 during first and second wave outbreak in Gwangju, Republic of Korea. <i>Scientific Reports</i> , 2022, 12, .	1.6	6
881	Evidence for yeast artificial synthesis in SARS-CoV-2 and SARS-CoV-1 genomic sequences. <i>F1000Research</i> , 0, 10, 912.	0.8	1
882	Protection of hamsters challenged with SARS-CoV-2 after two doses of MVC-COV1901 vaccine followed by a single intranasal booster with nanoemulsion adjuvanted S-2P vaccine. <i>Scientific Reports</i> , 2022, 12, .	1.6	4
883	Safety evaluation of MA-T after ingestion in mice. <i>Toxicology</i> , 2022, , 153254.	2.0	2
884	Human lung organoids as a model for respiratory virus replication and countermeasure performance in human hosts. <i>Translational Research</i> , 2022, 250, 36-45.	2.2	7
885	Prevalence and Mechanisms of Mucus Accumulation in COVID-19 Lung Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 206, 1336-1352.	2.5	28
886	Nasopharyngeal Bacterial Microbiota Composition and SARS-CoV-2 IgG Antibody Maintenance in Asymptomatic/Paucisymptomatic Subjects. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 12, .	1.8	3
887	COVID-19: Clinical, Immunological, and Image Findings from Infection to Post-COVID Syndrome. , 2022, , 76-98.		0
888	The Host Response to Influenza A Virus Interferes with SARS-CoV-2 Replication during Coinfection. <i>Journal of Virology</i> , 2022, 96, .	1.5	23
889	Immunomodulatory LncRNA on antisense strand of ICAM-1 augments SARS-CoV-2 infection-associated airway mucoinflammatory phenotype. <i>IScience</i> , 2022, 25, 104685.	1.9	6
890	Increasing contributions of airborne route in SARS-CoV-2 omicron variant transmission compared with the ancestral strain. <i>Building and Environment</i> , 2022, 221, 109328.	3.0	13

#	ARTICLE	IF	CITATIONS
891	Imaging Techniques: Essential Tools for the Study of SARS-CoV-2 Infection. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 12, .	1.8	4
892	A Bacteriophage-Based, Highly Efficacious, Needle- and Adjuvant-Free, Mucosal COVID-19 Vaccine. <i>MBio</i> , 2022, 13, .	1.8	17
893	Effectiveness of SARS-CoV-2 Vaccines for Short- and Long-Term Immunity: A General Overview for the Pandemic Contrast. <i>International Journal of Molecular Sciences</i> , 2022, 23, 8485.	1.8	6
894	Matrix Metalloproteinases Expression Is Associated with SARS-CoV-2-Induced Lung Pathology and Extracellular-Matrix Remodeling in K18-hACE2 Mice. <i>Viruses</i> , 2022, 14, 1627.	1.5	13
895	Human organoids: New strategies and methods for analyzing human development and disease. <i>Cell</i> , 2022, 185, 2756-2769.	13.5	42
896	Rapid initiation of nasal saline irrigation to reduce severity in high-risk COVID+ outpatients. <i>Ear, Nose and Throat Journal</i> , 0, , 014556132211237.	0.4	10
897	NOTCH signaling in COVID-19: a central hub controlling genes, proteins, and cells that mediate SARS-CoV-2 entry, the inflammatory response, and lung regeneration. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 12, .	1.8	12
898	Assessing suspension and infectivity times of virus-loaded aerosols involved in airborne transmission. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	15
900	Co-existence and co-infection of influenza A viruses and coronaviruses: Public health challenges. <i>Innovation(China)</i> , 2022, 3, 100306.	5.2	13
901	Home as the new frontier for the treatment of COVID-19: the case for anti-inflammatory agents. <i>Lancet Infectious Diseases</i> , The, 2023, 23, e22-e33.	4.6	38
902	Ancestral SARS-CoV-2, but not Omicron, replicates less efficiently in primary pediatric nasal epithelial cells. <i>PLoS Biology</i> , 2022, 20, e3001728.	2.6	15
903	Human Nasal Organoids Model SARS-CoV-2 Upper Respiratory Infection and Recapitulate the Differential Infectivity of Emerging Variants. <i>MBio</i> , 2022, 13, .	1.8	27
904	Reverse genetics in virology: A double edged sword. <i>Biosafety and Health</i> , 2022, 4, 303-313.	1.2	1
905	lâ€™ve looked at gut from both sides now: Gastrointestinal tract involvement in the pathogenesis of SARS-CoV-2 and HIV/SIV infections. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
907	COVID-19 and olfactory dysfunction: a looming wave of dementia?. <i>Journal of Neurophysiology</i> , 2022, 128, 436-444.	0.9	21
908	Preclinical immunogenicity and efficacy of a candidate COVID-19 vaccine based on a vesicular stomatitis virus-SARS-CoV-2 chimera. <i>EBioMedicine</i> , 2022, 82, 104203.	2.7	15
910	PIKfyve-specific inhibitors restrict replication of multiple coronaviruses in vitro but not in a murine model of COVID-19. <i>Communications Biology</i> , 2022, 5, .	2.0	7
911	Translational feasibility and efficacy of nasal photodynamic disinfection of SARS-CoV-2. <i>Scientific Reports</i> , 2022, 12, .	1.6	13

#	ARTICLE	IF	CITATIONS
912	Programmable antivirals targeting critical conserved viral RNA secondary structures from influenza A virus and SARS-CoV-2. <i>Nature Medicine</i> , 2022, 28, 1944-1955.	15.2	20
913	COVID-19 pandemic: A multidisciplinary perspective on the pathogenesis of a novel coronavirus from infection, immunity and pathological responses. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
915	ELF5 is a potential respiratory epithelial cell-specific risk gene for severe COVID-19. <i>Nature Communications</i> , 2022, 13, .	5.8	12
916	Host and microbiome features of secondary infections in lethal covid-19. <i>IScience</i> , 2022, 25, 104926.	1.9	10
917	A comprehensive insight into current control of COVID-19: Immunogenicity, vaccination, and treatment.. <i>Biomedicine and Pharmacotherapy</i> , 2022, 153, 113499.	2.5	12
918	A live-attenuated SARS-CoV-2 vaccine candidate with accessory protein deletions. <i>Nature Communications</i> , 2022, 13, .	5.8	51
919	Biosynthetic proteins targeting the SARS-CoV-2 spike as anti-virals. <i>PLoS Pathogens</i> , 2022, 18, e1010799.	2.1	2
920	Why is UIP peripheral?. <i>Expert Review of Respiratory Medicine</i> , 0, , 1-9.	1.0	0
921	Photochemical Identification of Auxiliary Severe Acute Respiratory Syndrome Coronavirus 2 Host Entry Factors Using $\frac{1}{4}$ Map. <i>Journal of the American Chemical Society</i> , 2022, 144, 16604-16611.	6.6	8
922	Revealing the mystery of persistent smell loss in long COVID patients. <i>International Journal of Biological Sciences</i> , 2022, 18, 4795-4808.	2.6	13
923	Pathogenetic connection of chronic sinusitis with polyps and new coronavirus infection. <i>Rossiiskaya Rinologiya</i> , 2022, 30, 192.	0.1	0
924	Loss of olfactory sensitivity is an early and reliable marker for COVID-19. <i>Chemical Senses</i> , 2022, 47, .	1.1	4
925	The airâ€“liquid interface model. , 2022, , 51-72.		0
926	COVID-19 Infection: The Virus and Its Origin, the Variants, the Immune Defense, the Multiorgan Autoimmune Reactions, and the Targeted Treatments. <i>Advances in Infectious Diseases</i> , 2022, 12, 568-631.	0.0	1
927	Taste disorders in disease. , 2023, , 407-436.		0
928	Stable nebulization and mucoâ€“trapping properties of regdanvimab/<sc>IN</sc>â€“006 support its development as a potent, doseâ€“saving inhaled therapy for <sc>COVID</sc>â€“19. <i>Bioengineering and Translational Medicine</i> , 2023, 8, .	3.9	10
929	Vandetanib Blocks the Cytokine Storm in SARS-CoV-2-Infected Mice. <i>ACS Omega</i> , 2022, 7, 31935-31944.	1.6	11
930	COVID-19-Related ARDS: Key Mechanistic Features and Treatments. <i>Journal of Clinical Medicine</i> , 2022, 11, 4896.	1.0	15

#	ARTICLE	IF	CITATIONS
931	Outcomes of Convalescent Plasma with Defined High versus Lower Neutralizing Antibody Titers against SARS-CoV-2 among Hospitalized Patients: CoronaVirus Inactivating Plasma (CoVIP) Study. MBio, 2022, 13, .	1.8	8
932	Protection against SARS-CoV-2 transmission by a parenteral primeâ€”Intranasal boost vaccine strategy. EBioMedicine, 2022, 84, 104248.	2.7	17
933	Overview of the Role of Spatial Factors in Indoor SARS-CoV-2 Transmission: A Space-Based Framework for Assessing the Multi-Route Infection Risk. International Journal of Environmental Research and Public Health, 2022, 19, 11007.	1.2	2
934	Japanese Knotweed Rhizome Bark Extract Inhibits Live SARS-CoV-2 In Vitro. Bioengineering, 2022, 9, 429.	1.6	2
935	Identification and Utilization of a Chemical Probe to Interrogate the Roles of PIKfyve in the Lifecycle of Î²-Coronaviruses. Journal of Medicinal Chemistry, 2022, 65, 12860-12882.	2.9	6
936	ACE2-containing defensosomes serve as decoys to inhibit SARS-CoV-2 infection. PLoS Biology, 2022, 20, e3001754.	2.6	17
937	Tracking Co-Occurrence of N501Y, P681R, and Other Key Mutations in SARS-CoV-2 Spike for Surveillance. , 2022, 2, 147-162.		4
938	Update on Extracellular Vesicle-Based Vaccines and Therapeutics to Combat COVID-19. International Journal of Molecular Sciences, 2022, 23, 11247.	1.8	7
939	Potential application of mass spectrometry imaging in pharmacokinetic studies. Xenobiotica, 2022, 52, 811-827.	0.5	2
940	Predicting the Kinetic Coordination of Immune Response Dynamics in SARS-CoV-2 Infection: Implications for Disease Pathogenesis. Mathematics, 2022, 10, 3154.	1.1	4
941	Lung Organoids as Model to Study SARS-CoV-2 Infection. Cells, 2022, 11, 2758.	1.8	8
942	In vitro activity of cysteamine against SARS-CoV-2 variants. Molecular Genetics and Metabolism, 2022, 137, 192-200.	0.5	5
943	Quantitative proteomic analysis of SARS-CoV-2 infection of primary human airway ciliated cells and lung epithelial cells demonstrates the effectiveness of SARS-CoV-2 innate immune evasion. Wellcome Open Research, 0, 7, 224.	0.9	2
944	Native and activated antithrombin inhibits TMPRSS2 activity and SARSâ€”infection. Journal of Medical Virology, 2023, 95, .	2.5	13
945	Ultracellular Imaging of Bronchoalveolar Lavage from Young COVID-19 Patients with Comorbidities Showed Greater SARS-COV-2 Infection but Lesser Ultrastructural Damage Than the Older Patients. Microscopy and Microanalysis, 2022, 28, 2105-2129.	0.2	3
946	Hypoxia inducible factors regulate infectious SARS-CoV-2, epithelial damage and respiratory symptoms in a hamster COVID-19 model. PLoS Pathogens, 2022, 18, e1010807.	2.1	15
947	New Insights into the Alveolar Epithelium as a Driver of Acute Respiratory Distress Syndrome. Biomolecules, 2022, 12, 1273.	1.8	9
949	Metalloprotease-Dependent S2â€”Activation Promotes Cellâ€”Cell Fusion and Syncytiation of SARS-CoV-2. Viruses, 2022, 14, 2094.	1.5	6

#	ARTICLE	IF	CITATIONS
950	Pharmacokinetic considerations to optimize clinical outcomes for COVID-19 drugs. Trends in Pharmacological Sciences, 2022, 43, 1041-1054.	4.0	4
951	Proviral role of caspase-6 in coronavirus infections. Cell Research, 0, , .	5.7	1
952	A Study on the Fractal-Fractional Epidemic Probability-Based Model of SARS-CoV-2 Virus along with the Taylor Operational Matrix Method for Its Caputo Version. Journal of Function Spaces, 2022, 2022, 1-33.	0.4	4
953	COVID-19 and cellular senescence. Nature Reviews Immunology, 2023, 23, 251-263.	10.6	54
955	A hybrid discrete-continuum model of immune responses to SARS-CoV-2 infection in the lung alveolar region, with a focus on interferon induced innate response. Journal of Theoretical Biology, 2022, 555, 111293.	0.8	5
956	A single intranasal administration of AdCOVID protects against SARS-CoV-2 infection in the upper and lower respiratory tracts. Human Vaccines and Immunotherapeutics, 2022, 18, .	1.4	9
957	Quantification of Dark Protein Populations in Fluorescent Proteins by Two-Color Coincidence Detection and Nanophotonic Manipulation. Journal of Physical Chemistry B, 0, , .	1.2	1
960	Single-cell analytical technologies: uncovering the mechanisms behind variations in immune responses. FEBS Journal, 2024, 291, 819-831.	2.2	0
961	IgG-like bispecific antibodies with potent and synergistic neutralization against circulating SARS-CoV-2 variants of concern. Nature Communications, 2022, 13, .	5.8	5
962	Quantifying Intracellular Viral Pathogen: Specimen Preparation, Visualization and Quantification of Multiple Immunofluorescent Signals in Fixed Human Airway Epithelium Cultured at Air-Liquid Interface. Journal of Personalized Medicine, 2022, 12, 1668.	1.1	2
963	Antibody protection from SARS-CoV-2 respiratory tract exposure and infection. Journal of Theoretical Biology, 2023, 557, 111334.	0.8	5
964	SARS-CoV-2 cellular tropism and direct multiorgan failure in COVID-19 patients: Bioinformatic predictions, experimental observations, and open questions. Cell Biology International, 2023, 47, 308-326.	1.4	7
965	Spike protein mediated membrane fusion during SARS-CoV-2 infection. Journal of Medical Virology, 2023, 95, .	2.5	15
966	SARS-CoV-2 Omicron variant is attenuated for replication in a polarized human lung epithelial cell model. Communications Biology, 2022, 5, .	2.0	34
967	Harnessing Nasal Immunity with IgA to Prevent Respiratory Infections. Immuno, 2022, 2, 571-583.	0.6	5
968	PATHOGENESIS OF COVID-19. Tavriġeskij Mediko-biologiġeskij Vestnik, 2022, 23, 113-132.	0.1	3
969	Lack of Benefit of High Flow Nasal Oxygen Therapy as Ceiling of Treatment for Severe COVID-19 Pneumonitis in Elderly Frail Patients: A Single Centre Observational Study. Open Respiratory Medicine Journal, 2022, 16, .	1.3	0
970	Membrane attachment and fusion of HIV-1, influenza A, and SARS-CoV-2: resolving the mechanisms with biophysical methods. Biophysical Reviews, 2022, 14, 1109-1140.	1.5	15

#	ARTICLE	IF	CITATIONS
971	Development of fluorescent lateral flow immunoassay for SARS-CoV-2-specific IgM and IgG based on aggregation-induced emission carbon dots. <i>Frontiers in Bioengineering and Biotechnology</i> , 0, 10, .	2.0	10
972	SARS-CoV-2 Variant-Specific Infectivity and Immune Profiles Are Detectable in a Humanized Lung Mouse Model. <i>Viruses</i> , 2022, 14, 2272.	1.5	3
973	Nebulized mRNA-Encoded Antibodies Protect Hamsters from SARS-CoV-2 Infection. <i>Advanced Science</i> , 2022, 9, .	5.6	12
974	Enhanced metanephric specification to functional proximal tubule enables toxicity screening and infectious disease modelling in kidney organoids. <i>Nature Communications</i> , 2022, 13, .	5.8	27
975	A proteome-scale map of the SARS-CoV-2-human contactome. <i>Nature Biotechnology</i> , 2023, 41, 140-149.	9.4	29
976	Patient factors associated with COVID-19 loss of taste or smell patient factors in smell/taste loss COVID-19. <i>Laryngoscope Investigative Otolaryngology</i> , 0, , .	0.6	1
978	DNA damage contributes to age-associated differences in SARS-CoV-2 infection. <i>Aging Cell</i> , 2022, 21, .	3.0	10
979	Intranasal nanoemulsion adjuvanted S-2P vaccine demonstrates protection in hamsters and induces systemic, cell-mediated and mucosal immunity in mice. <i>PLoS ONE</i> , 2022, 17, e0272594.	1.1	1
980	S-217622, a SARS-CoV-2 main protease inhibitor, decreases viral load and ameliorates COVID-19 severity in hamsters. <i>Science Translational Medicine</i> , 2023, 15, .	5.8	39
981	Differential effects of age, sex and dexamethasone therapy on ACE2/TMPRSS2 expression and susceptibility to SARS-CoV-2 infection. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
982	Identification and differential usage of a host metalloproteinase entry pathway by SARS-CoV-2 Delta and Omicron. <i>IScience</i> , 2022, 25, 105316.	1.9	16
983	Snoring may transmit infectious aerosols from the upper to the lower respiratory tract. <i>Medical Hypotheses</i> , 2022, 168, 110966.	0.8	1
985	Effect of 0.5% povidone-iodine on the nasopharyngeal and oropharyngeal viral loads in patients with COVID-19: A double-blind placebo-controlled randomized clinical trial. <i>Journal of Family Medicine and Primary Care</i> , 2022, 11, 6320.	0.3	0
986	Vascular dysfunction in COVID-19 patients: update on SARS-CoV-2 infection of endothelial cells and the role of long non-coding RNAs. <i>Clinical Science</i> , 2022, 136, 1571-1590.	1.8	7
987	The Expression Levels of SARS-CoV-2 Infection-Mediating Molecules Promoted by Interferon- β and Tumor Necrosis Factor- α Are Downregulated by Hydrogen Sulfide. <i>International Journal of Molecular Sciences</i> , 2022, 23, 13624.	1.8	1
988	An intranasal vaccine targeting the receptor binding domain of SARS-CoV-2 elicits a protective immune response. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
989	SARS-CoV-2 variant Alpha has a spike-dependent replication advantage over the ancestral B.1 strain in human cells with low ACE2 expression. <i>PLoS Biology</i> , 2022, 20, e3001871.	2.6	11
990	Impact of upper and lower respiratory symptoms on COVID-19 outcomes: a multicenter retrospective cohort study. <i>Respiratory Research</i> , 2022, 23, .	1.4	10

#	ARTICLE	IF	CITATIONS
992	Human lung organoid: Models for respiratory biology and diseases. <i>Developmental Biology</i> , 2023, 494, 26-34.	0.9	5
993	Counter-regulatory renin-angiotensin system in hypertension: Review and update in the era of COVID-19 pandemic. <i>Biochemical Pharmacology</i> , 2023, 208, 115370.	2.0	7
994	An overview of viral mutagenesis and the impact on pathogenesis of SARS-CoV-2 variants. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	7
996	Assessment of SARS-CoV-2 entry in gingival epithelial cells expressing CD147. <i>European Journal of Oral Sciences</i> , 0, , .	0.7	0
997	Nanomaterials to combat SARS-CoV-2: Strategies to prevent, diagnose and treat COVID-19. <i>Frontiers in Bioengineering and Biotechnology</i> , 0, 10, .	2.0	3
999	Silver nanoparticles with excellent biocompatibility block pseudotyped SARS-CoV-2 in the presence of lung surfactant. <i>Frontiers in Bioengineering and Biotechnology</i> , 0, 10, .	2.0	1
1000	Overcoming Barriers to Preventing and Treating <i>P. aeruginosa</i> Infections Using AAV Vected Immunoprophylaxis. <i>Biomedicines</i> , 2022, 10, 3162.	1.4	2
1001	Sex hormones in SARS-CoV-2 susceptibility: key players or confounders?. <i>Nature Reviews Endocrinology</i> , 2023, 19, 217-231.	4.3	11
1002	SARS-CoV-2 replication in airway epithelia requires motile cilia and microvillar reprogramming. <i>Cell</i> , 2023, 186, 112-130.e20.	13.5	72
1003	Evaluation of a COVID-19 convalescent plasma program at a U.S. academic medical center. <i>PLoS ONE</i> , 2022, 17, e0277707.	1.1	1
1004	AZD1222-induced nasal antibody responses are shaped by prior SARS-CoV-2 infection and correlate with virologic outcomes in breakthrough infection. <i>Cell Reports Medicine</i> , 2023, 4, 100882.	3.3	10
1005	An epithelial-immune circuit amplifies inflammasome and IL-6 responses to SARS-CoV-2. <i>Cell Host and Microbe</i> , 2023, 31, 243-259.e6.	5.1	20
1006	Reverse genetic systems of SARS-CoV-2 for antiviral research. <i>Antiviral Research</i> , 2023, 210, 105486.	1.9	12
1007	Biosensors - A Miraculous Detecting Tool in Combating the War against COVID-19. <i>Current Pharmaceutical Biotechnology</i> , 2023, 24, .	0.9	0
1008	S Protein, ACE2 and Host Cell Proteases in SARS-CoV-2 Cell Entry and Infectivity; Is Soluble ACE2 a Two Blade Sword? A Narrative Review. <i>Vaccines</i> , 2023, 11, 204.	2.1	5
1009	COVID-19 and hepatic injury: Diversity and risk assessment. <i>World Journal of Gastroenterology</i> , 0, 29, 425-449.	1.4	5
1010	A novel mRNA vaccine, SYS6006, against SARS-CoV-2. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	12
1011	Do SARS-CoV-2 Variants Differ in Their Neuropathogenicity?. <i>MBio</i> , 0, , .	1.8	1

#	ARTICLE	IF	CITATIONS
1012	The nasopharyngeal microbiome in COVID-19. <i>Emerging Microbes and Infections</i> , 2023, 12, .	3.0	14
1013	Human Adenovirus and Influenza A Virus Exacerbate SARS-CoV-2 Infection in Animal Models. <i>Microorganisms</i> , 2023, 11, 180.	1.6	4
1014	Commonly used dental mouthwashes and <sc>SARS CoV</sc> – the road to what we know today. <i>Oral Surgery</i> , 0, , .	0.1	0
1015	Open questions in human lung organoid research. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	1
1016	First Evidence of the Protective Effects of 2-Pentadecyl-2-Oxazoline (PEA-OXA) in In Vitro Models of Acute Lung Injury. <i>Biomolecules</i> , 2023, 13, 33.	1.8	2
1017	Bystander effect of SARS-CoV-2 spike protein on human monocytic THP-1 cell activation and initiation of prothrombotic stimulus representing severe COVID-19. <i>Journal of Inflammation</i> , 2022, 19, .	1.5	4
1019	Pulmonary fibrosis: A short- or long-term sequelae of severe COVID-19?. , 2023, 1, 77-83.		3
1020	CellPalmSeq: A curated RNAseq database of palmitoylating and de-palmitoylating enzyme expression in human cell types and laboratory cell lines. <i>Frontiers in Physiology</i> , 0, 14, .	1.3	8
1021	Targeting Viral ORF3a Protein: A New Approach to Mitigate COVID-19 Induced Immune Cell Apoptosis and Associated Respiratory Complications. <i>Advanced Pharmaceutical Bulletin</i> , 2023, 13, 678-687.	0.6	1
1022	Prediction of transport, deposition, and resultant immune response of nasal spray vaccine droplets using a CFD-HCD model in a 6-year-old upper airway geometry to potentially prevent COVID-19. <i>Experimental and Computational Multiphase Flow</i> , 0, , .	1.9	1
1023	Inhalation of virus-loaded droplets as a clinically plausible pathway to deep lung infection. <i>Frontiers in Physiology</i> , 0, 14, .	1.3	1
1024	Innate immune recognition against SARS-CoV-2. <i>Inflammation and Regeneration</i> , 2023, 43, .	1.5	8
1025	<i>Solanum nigrum</i> L. in COVID-19 and post-COVID complications: a propitious candidate. <i>Molecular and Cellular Biochemistry</i> , 0, , .	1.4	0
1026	Design of a chimeric ACE-2/Fc-silent fusion protein with ultrahigh affinity and neutralizing capacity for SARS-CoV-2 variants. <i>Antibody Therapeutics</i> , 2023, 6, 59-74.	1.2	0
1027	An Innate Checkpoint Determines Immune Dysregulation and Immunopathology during Pulmonary Murine Coronavirus Infection. <i>Journal of Immunology</i> , 2023, 210, 774-785.	0.4	2
1028	ACE2 in pulmonary diseases. , 2023, , 285-316.		0
1029	Quantitative analysis of high-throughput biological data. <i>Wiley Interdisciplinary Reviews: Computational Molecular Science</i> , 2023, 13, .	6.2	2
1030	Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	23

#	ARTICLE	IF	CITATIONS
1031	In SARS-CoV-2 delta variants, Spike-P681R and D950N promote membrane fusion, Spike-P681R enhances spike cleavage, but neither substitution affects pathogenicity in hamsters. <i>EBioMedicine</i> , 2023, 91, 104561.	2.7	14
1032	Tight junction protein occludin is an internalization factor for SARS-CoV-2 infection and mediates virus cell-to-cell transmission. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2023, 120, .	3.3	3
1033	Modeling identifies variability in SARS-CoV-2 uptake and eclipse phase by infected cells as principal drivers of extreme variability in nasal viral load in the 48h post infection. <i>Journal of Theoretical Biology</i> , 2023, 565, 111470.	0.8	5
1034	Epidemiological Characteristics, Pathogenesis and Clinical Implications of Sinusitis in the Era of COVID-19: A Narrative Review. <i>Journal of Asthma and Allergy</i> , 0, Volume 16, 201-211.	1.5	0
1035	Differential haplotype expression in class I MHC genes during SARS-CoV-2 infection of human lung cell lines. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
1036	The Spread of SARS-CoV-2 Omicron Variant in CALABRIA: A Spatio-Temporal Report of Viral Genome Evolution. <i>Viruses</i> , 2023, 15, 408.	1.5	6
1037	Angiotensin-converting enzyme 2 at the heart of the COVID-19 pandemic. <i>Cell</i> , 2023, 186, 906-922.	13.5	36
1038	Cell-autonomous requirement for ACE2 across organs in lethal mouse SARS-CoV-2 infection. <i>PLoS Biology</i> , 2023, 21, e3001989.	2.6	6
1039	SARS-CoV-2 Viremia Precedes an IL6 Response in Severe COVID-19 Patients: Results of a Longitudinal Prospective Cohort. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	4
1040	SARS-CoV-2 leverages airway epithelial protective mechanism for viral infection. <i>IScience</i> , 2023, 26, 106175.	1.9	2
1041	Viral Mitigation: Weak Theoretical Underpinnings. <i>Studies in Public Choice</i> , 2023, , 9-58.	0.0	0
1043	Adenoviral Vector-Based Vaccine Platform for COVID-19: Current Status. <i>Vaccines</i> , 2023, 11, 432.	2.1	17
1044	Association between serum ferritin level and decreased diffusion capacity 3 months after the onset of COVID-19 pneumonia. <i>PLoS ONE</i> , 2023, 18, e0281249.	1.1	2
1045	Transient Positive SARS-CoV-2 PCR without Induction of Systemic Immune Responses. <i>Vaccines</i> , 2023, 11, 482.	2.1	0
1046	Human ACE2 expression, a major tropism determinant for SARS-CoV-2, is regulated by upstream and intragenic elements. <i>PLoS Pathogens</i> , 2023, 19, e1011168.	2.1	8
1047	Study of the Effects of Several SARS-CoV-2 Structural Proteins on Antiviral Immunity. <i>Vaccines</i> , 2023, 11, 524.	2.1	3
1048	Dissecting Phenotype from Genotype with Clinical Isolates of SARS-CoV-2 First Wave Variants. <i>Viruses</i> , 2023, 15, 611.	1.5	1
1049	Insights into organoid-based modeling of COVID-19 pathology. <i>Virology Journal</i> , 2023, 20, .	1.4	1

#	ARTICLE	IF	CITATIONS
1050	COVID-19 Biogenesis and Intracellular Transport. International Journal of Molecular Sciences, 2023, 24, 4523.	1.8	7
1051	Nasal sprays for treating COVID-19: a scientific note. Pharmacological Reports, 2023, 75, 249-265.	1.5	10
1052	Coronavirus accessory protein ORF3 biology and its contribution to viral behavior and pathogenesis. IScience, 2023, 26, 106280.	1.9	9
1053	The Defenders of the Alveolus Succumb in COVID-19 Pneumonia to SARS-CoV-2 and Necroptosis, Pyroptosis, and PANoptosis. Journal of Infectious Diseases, 2023, 227, 1245-1254.	1.9	6
1055	Application of the PHENotype SIMulator for rapid identification of potential candidates in effective COVID-19 drug repurposing. Heliyon, 2023, 9, e14115.	1.4	1
1056	Cellular and Molecular Mechanisms of Pathogenic and Protective Immune Responses to SARS-CoV-2 and Implications of COVID-19 Vaccines. Vaccines, 2023, 11, 615.	2.1	2
1058	Cigarette smoke preferentially induces full length ACE2 expression in differentiated primary human airway cultures but does not alter the efficiency of cellular SARS-CoV-2 infection. Heliyon, 2023, 9, e14383.	1.4	1
1059	Computational optimization of delivery parameters to guide the development of targeted Nasal spray. Scientific Reports, 2023, 13, .	1.6	1
1060	Importance, Applications and Features of Assays Measuring SARS-CoV-2 Neutralizing Antibodies. International Journal of Molecular Sciences, 2023, 24, 5352.	1.8	7
1061	Motile cilia and microvillar: accomplices of SARS-CoV-2 in penetrating mucus barrier and infecting airway epithelium. Signal Transduction and Targeted Therapy, 2023, 8, .	7.1	2
1062	The accuracy of reverse genetics systems for SARS-CoV-2: Circular polymerase extension reaction versus bacterial artificial chromosome. Influenza and Other Respiratory Viruses, 2023, 17, .	1.5	4
1064	COVID-19 as a Trigger for Type 1 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2023, 108, 2176-2183.	1.8	8
1065	Intranasal trimeric sherpabody inhibits SARS-CoV-2 including recent immunoevasive Omicron subvariants. Nature Communications, 2023, 14, .	5.8	6
1066	Three-dimensional morphologic and molecular atlases of nasal vasculature. , 2023, 2, 449-466.		1
1067	Impact of Changes in Human Airway Epithelial Cellular Composition and Differentiation on SARS-CoV-2 Infection Biology. Journal of Innate Immunity, 2023, 15, 562-580.	1.8	2
1068	Effect of the povidone iodine, hypertonic alkaline solution and saline nasal lavage on nasopharyngeal viral load in COVID-19. Clinical Otolaryngology, 2023, 48, 623-629.	0.6	0
1069	Type 2 inflammation reduces SARS-CoV-2 replication in the airway epithelium in allergic asthma through functional alteration of ciliated epithelial cells. Journal of Allergy and Clinical Immunology, 2023, 152, 56-67.	1.5	9
1070	Fc-mediated pan-sarbecovirus protection after alphavirus vector vaccination. Cell Reports, 2023, 42, 112326.	2.9	13

#	ARTICLE	IF	CITATIONS
1072	Pulmonary Manifestations of COVID-19. , 2024, , 100-136.		0
1074	Infection of primary nasal epithelial cells differentiates among lethal and seasonal human coronaviruses. Proceedings of the National Academy of Sciences of the United States of America, 2023, 120, .	3.3	12
1075	SARS-CoV-2: Structure, Pathogenesis, and Diagnosis. , 2024, , 24-51.		0
1076	Promises and challenges of mucosal COVID-19 vaccines. Vaccine, 2023, 41, 4042-4049.	1.7	5
1077	Human airway and nasal organoids reveal escalating replicative fitness of SARS-CoV-2 emerging variants. Proceedings of the National Academy of Sciences of the United States of America, 2023, 120, .	3.3	16
1078	Consistent Effects of Early Remdesivir on Symptoms and Disease Progression Across At-Risk Outpatient Subgroups: Treatment Effect Heterogeneity in PINETREE Study. Infectious Diseases and Therapy, 2023, 12, 1189-1203.	1.8	6
1080	Organotypic human lung bud microarrays identify BMP-dependent SARS-CoV-2 infection in lung cells. Stem Cell Reports, 2023, , .	2.3	0
1081	Exhaled aerosols among PCR-confirmed SARS-CoV-2-infected children. Frontiers in Pediatrics, 0, 11, .	0.9	0
1096	SARS-CoV (COVID-19 and SARS). , 2024, , 812-818.		1
1190	Non-coding RNAs expression in SARS-CoV-2 infection: pathogenesis, clinical significance, and therapeutic targets. Signal Transduction and Targeted Therapy, 2023, 8, .	7.1	0
1203	Early Prediction of COVID-19 Patient Survival by Blood Plasma Using Machine Learning. , 2023, , .		0
1214	Coronavirus and the Cytoskeleton of Virus-Infected Cells. Sub-Cellular Biochemistry, 2023, , 333-364.	1.0	0
1215	Mesenchymal stromal cells and pleiotropic therapeutic advantages in COVID-19 management. , 2024, , 279-306.		0
1224	Pathogenesis of viral infection. , 2024, , 2187-2207.		0